Lentiviral vectors for the expression of human papillomavirus (HPV) antigens and their implementation in the treatment of HPV-induced cancers

Non-integrating lentiviral vectors expressing HPV16/18 E6/E7 antigens, combined with immune checkpoint inhibitors, effectively address the limitations of current HPV vaccines by inducing robust immune responses and complete tumor elimination.

JP2024544566APending Publication Date: 2024-12-03セラベクティス +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
JP2024528594
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-27
Filing Date
2022-11-14
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current therapeutic vaccines for HPV-induced cancers, particularly those with aggressive and well-engrafted tumors, face challenges in complete elimination and are ineffective against strong regulatory T cell infiltration, necessitating improved immunological memory and safety.

Method used

Development of non-integrating lentiviral vectors expressing non-oncogenic HPV16 and HPV18 E6/E7 antigens, combined with immune checkpoint inhibitors, to enhance CD8+ T cell infiltration and induce strong, sustained immune responses.

Benefits of technology

The lentiviral vectors demonstrate potent therapeutic and prophylactic activity against HPV-induced tumors, achieving complete tumor elimination and long-lasting immunity with reduced Treg cells, even in aggressive tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544566000006
    Figure 2024544566000006
  • Figure 2024544566000007
    Figure 2024544566000007
  • Figure 2024544566000008
    Figure 2024544566000008
Patent Text Reader

Abstract

The present invention relates to a lentiviral vector, in particular a non-integrating lentiviral vector, comprising at least four different nucleic acid sequences encoding HPV antigens, to a lentiviral vector particle comprising said vector, to an isolated cell comprising said lentiviral vector or said lentiviral vector particle, as well as a vaccine composition comprising said lentiviral vector, lentiviral vector particle or cell. The present invention further relates to their implementation in the treatment or prevention of HPV-induced cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of recombinant vaccine technology and to improvements in lentiviral vectors that can be used as therapeutic and prophylactic vaccines. In particular, the present invention relates to lentiviral vectors expressing Human Papillomavirus (HPV) antigens and their implementation in the prevention and treatment of HPV induced cancers. [Background technology]

[0002] HPV accounts for 5.2% of cancers worldwide (Tota et al., Prev Med 2011 Oct; 53 Suppl 1:S12-21). More than 100 HPV types have been identified and classified into three groups depending on their association with cancer: high-risk types with high carcinogenicity (among them, HPV type 16 (HPV-16) and HPV type 18 (HPV-18)), low-risk types associated with benign lesions (HPV-6, -11) and cutaneous types (among them, HPV-1, -2, -3, -4...) (Chen et al.Virology vol.516 (2018):86-101). The proportion of HPV-associated cancers varies by cancer type and region, but it is estimated that 90% of cervical cancers, 91% of anal cancers, 75% of vaginal cancers, 70% of oropharyngeal cancers, 69% of vulvar cancers, and 63% of penile cancers are associated with HPV infection (Saraiya et al.,J Natl Cancer Inst.2015 Apr 29;107(6)).

[0003] The two most common types of HPV in cancer are HPV16 and HPV18. For example, HPV16 and HPV18 are thought to be involved in 70-75% of all cervical cancers (de Sanjose et al.,Eur J Cancer.2013 Nov;49(16):3450-61). HPV16 and 18 are also significantly involved in anal cancer (91%), oropharyngeal cancer (70%), vaginal cancer (75%), penile cancer (63%) and vulvar cancer (68%) (Saraiya et al.,J Natl Cancer Inst.2015 Apr 29;107(6)).

[0004] Thereby, therapeutic vaccines targeting HPV16 / 18 could potentially be used to treat and prevent associated cancers, regardless of site.

[0005] Human papillomaviruses (HPV) are non-enveloped, double-stranded DNA viruses. Their genomes encode six nonstructural proteins (early proteins E1, E2, E4, E5, E6, and E7) and two structural proteins (late proteins L1 and L2) (Chen et al. Virology vol. 516 (2018):86-101).

[0006] Of these proteins, E6 and E7 have been well characterized for their oncogenic properties. E6 and E7 are known to inactivate p53 and pRb tumor suppressor proteins, thereby promoting cell proliferation. The E6 / E7 oncogenes are important for both inducing HPV-associated malignant cell transformation and maintaining the oncogenic phenotype of HPV-positive cancer cells (Yim and Park, Cancer Res Treat. 2005 Dec;37(6):319-24). E6 and E7 proteins are expressed by all HPV-positive cells throughout infection, an observation that makes them perfect targets for a vaccine.

[0007] Recombinant viral vectors have been widely developed for vaccination purposes. Modification of viral genomes has allowed the production of non-toxic and non-infectious viral particles that can be used as tools to introduce genetic material into target cells. Inducing T cell-mediated immunity using recombinant viral vectors is a very promising approach for vaccination. Various viral vectors, including retroviral vectors, adenoviral vectors, and vaccinia viral vectors, have been evaluated for vaccination purposes (Milone and O'Doherty, Leukemia (2018) 32:1529-1541 and Ku et al., Expert Review of Vaccines (2021)). Lentiviruses are part of the retroviridae family, which includes human immunodeficiency viruses (HIV). Lentiviral vectors are mainly derived from HIV-1. The safety of lentiviral vectors is improved by removing the LTR U3 sequences, resulting in a "self-inactivating" vector that is completely devoid of viral promoter and enhancer sequences. Lentiviral vectors have emerged as promising tools because they show several advantages over other viral systems. In particular, lentiviral vectors are non-toxic and, unlike other retroviruses, are able to transduce non-dividing cells, especially dendritic cells (He et al. 2007, Expert Rev vaccines, 6(6):913-24), allowing sustained antigen presentation through the endogenous pathway.

[0008] In contrast to other commonly used viral vectors, lentiviral vectors have the ability to transduce non-dividing cells. Efficient gene transfer in non-dividing cells requires the formation of a triple-stranded DNA structure called the central DNA "flap", which maximizes the efficiency of gene transfer into the nucleus of non-dividing cells, including dendritic cells (DCs) (Arhel et al., EMBO J. 2007 Jun 20; 26(12): 3025-3037) (Zennou et al., Cell. 2000 Apr 14; 101(2): 173-85).

[0009] Dendritic cells (DCs) are the major class of antigen presenting cells (APCs) and are of paramount importance for antigen presentation, since their main function is to present antigens and initiate immune responses (Steinman, R., Banchereau, J. Nature 449, 419-426 (2007)). Mature DCs migrate to draining lymph nodes, where they present short peptides derived from antigens on their surface through major histocompatibility complex (MHC) molecules. Antigen-specific T cells present in the lymph nodes can then interact with the peptide-MHC complexes through their TCRs (T Cell Receptors). Recognition of peptide-MHC by specific TCRs, coupled with costimulatory signals, initiates T cell activation (Steinman, R., Banchereau, J. Nature 449, 419-426 (2007)).

[0010] It is an object of the present invention to provide therapeutic and prophylactic vaccines for the prevention and treatment of HPV-induced cancers.

[0011] Therapeutic vaccination against high-risk human papillomaviruses using an integrase-deficient lentiviral vector expressing non-oncogenic HPV16 E7 fused to calreticulin (CRT) has been reported (Grasso et al. 2013 Jan 15;132(2):335-44). The study was performed on early stage tumors and demonstrated the ability of this construct to eradicate the tumors in a reasonable, but not complete, number of vaccinated mice.

[0012] Thus, there remains a need in the art for treatments for the more aggressive and / or well-implanted tumors induced by HPV, which are known in the art to be more difficult to eliminate than small and early stage tumors.

[0013] There is a need for treatment of HPV-induced resistant tumors, tumors characterized by a strong infiltration of Regulatory T cells (Treg).

[0014] Moreover, it is also possible to reduce Tregs in the HPV-induced tumors to be treated while increasing CD8 + and CD4 + There is a need for therapeutic vaccines that allow for cellular infiltration.

[0015] There is also a need for the development of strong immunological memory against HPV, in particular against PDHPV antigens, and more particularly against HPV16 and HPV18 antigens.

[0016] There is also a need for the development of new vaccines that are safe, non-oncogenic, preventive and therapeutic against HPV-induced cancers.

[0017] There is further a need for a vaccine that allows for complete elimination of the primary tumor with a single administration and provides strong protection against recurrence. Summary of the Invention [Problem to be solved by the invention]

[0018] The present invention aims to meet the above-mentioned needs. [Means for solving the problem]

[0019] Accordingly, the present invention relates to the following items:

[0020] Item 1: At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen, At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen, At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and At least one nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen A lentiviral vector, particularly a non-integrative lentiviral vector, comprising at least four different nucleic acid sequences selected from the group consisting of:

[0021] As shown in the examples, the lentiviral vectors of the invention enable potent therapeutic and prophylactic activity against HPV-induced tumors.

[0022] Item 2: 2. The lentiviral vector according to item 1, wherein the nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen encodes an amino acid sequence having at least 80% sequence identity with the amino acid sequence set forth as SEQ ID NO:7, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

[0023] Item 3: 3. The lentiviral vector according to item 1 or 2, wherein the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus (HPV16) protein E7 antigen encodes an amino acid sequence having at least 68% sequence identity with the amino acid sequence set forth as SEQ ID NO: 16, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO: 14 and SEQ ID NO: 15.

[0024] Item 4: 4. The lentiviral vector according to any one of items 1 to 3, wherein the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus (HPV18) protein E6 antigen encodes an amino acid sequence having at least 60% sequence identity with the amino acid sequence set forth as SEQ ID NO:24, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

[0025] Item 5: 5. The lentiviral vector according to any one of items 1 to 4, wherein the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus (HPV18) protein E7 antigen encodes an amino acid sequence having at least 83% sequence identity with the amino acid sequence set forth as SEQ ID NO: 33, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32.

[0026] Item 6: 6. The lentiviral vector according to any one of items 1 to 5, wherein the at least four different nucleic acid sequences encoding antigens are fused together to form a single antigen nucleic acid sequence encoding a single antigen fusion protein under the control of a single promoter sequence.

[0027] Item 7: The at least four different nucleic acid sequences are in the following order from the 5' end to the 3' end: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen; (b) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen; (c) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen; and (d) a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen. 7. The lentiviral vector according to any one of items 1 to 6, selected from the group consisting of:

[0028] Item 8: 8. The lentiviral vector according to any one of items 1 to 7, wherein the at least four different nucleic acid sequences are in the following order from the 5' end to the 3' end: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen.

[0029] Item 9: 9. The lentiviral vector according to any one of items 1 to 8, comprising a nucleic acid sequence encoding an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth as SEQ ID NO: 42, wherein the nucleic acid sequence is in particular the nucleic acid sequence SEQ ID NO: 41.

[0030] Item 10: 10. The lentiviral vector according to any one of items 1 to 9, wherein the lentiviral vector is selected from the group consisting of the non-integrating lentiviral vectors deposited at the CNCM under accession numbers I-5759, I-5760, I-5761 and I-5762, in particular the non-integrating lentiviral vector deposited at the CNCM under accession number I-5759.

[0031] Item 11: 11. The lentiviral vector according to any one of items 1 to 10, wherein the lentiviral vector comprises an MHC class I promoter, in particular a β2-microglobulin promoter.

[0032] Item 12: 12. The lentiviral vector according to any one of items 1 to 11, wherein the lentiviral vector comprises a cPPT / CTS sequence, in particular the cPPT / CTS sequence set forth as nucleic acid sequence SEQ ID NO: 37.

[0033] Item 13: 13. The lentiviral vector according to any one of items 1 to 12, wherein the lentiviral vector comprises a 3' long terminal repeat (LTR) lacking a U3 promoter sequence.

[0034] Item 14: 14. The lentiviral vector according to any one of items 1 to 13, wherein the lentiviral vector does not comprise a constitutive enhancer sequence.

[0035] Item 15: 15. The non-integrative lentiviral vector according to any one of items 1 to 14, wherein the lentiviral vector comprises a mutated form of the Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE), in particular comprising said mutated form having the nucleic acid sequence set forth as SEQ ID NO: 38.

[0036] Item 16: 16. A lentiviral vector particle, in particular a non-integrating lentiviral vector particle, comprising at least one lentiviral vector according to any one of items 1 to 15.

[0037] Item 17: 17. The lentiviral vector particle of item 16, wherein the lentiviral vector particle comprises a functional lentiviral integrase protein.

[0038] Item 18: 18. The lentiviral vector particle according to item 16 or 17, wherein the lentiviral vector particle comprises a vesicular stomatitis virus glycoprotein (VSVG), in particular VSV-G Indiana serotype or VSV-G New Jersey serotype.

[0039] Item 19: 19. The lentiviral vector particle according to any one of items 16 to 18, wherein the lentiviral vector particle comprises HIV-1 subtype D Gag and Pol proteins.

[0040] Item 20: An isolated cell comprising the lentiviral vector according to any one of items 1 to 15 or the lentiviral vector particle according to any one of items 16 to 19.

[0041] Item 21: A vaccine composition comprising the lentiviral vector according to any one of items 1 to 15, the lentiviral vector particle according to any one of items 16 to 19, or the cell according to item 20.

[0042] Item 22: 22. The vaccine composition according to item 21 for use in the treatment or prevention of HPV-induced cancers, in particular cancers selected from the group consisting of cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer, oropharyngeal cancer, and metastases thereof, in particular lung metastases thereof.

[0043] Item 23: 21. The lentiviral vector according to any one of items 1 to 15, the lentiviral vector particle according to any one of items 16 to 19, or the cell according to item 20, for use as a pharmaceutical or vaccine.

[0044] Item 24: 24. The lentiviral vector, lentiviral vector particle or cell according to item 23 for use in the treatment or prevention of HPV-induced cancer, in particular a cancer selected from the group consisting of cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer, oropharyngeal cancer and metastases thereof, in particular lung metastases thereof.

[0045] Item 25: 25. The vaccine composition for use according to item 22 or the lentiviral vector, lentiviral vector particle or cell for use according to item 23 or 24, wherein the vaccine composition, lentiviral vector, lentiviral vector particle or cell is administered in combination with at least one immune checkpoint inhibitor, in particular in combination with at least one monoclonal antibody selected from the group consisting of anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-NKG2A, anti-TIM-3, anti-TIGIT and anti-LAG-3 monoclonal antibodies, more in particular in combination with at least one anti-PD-1 monoclonal antibody.

[0046] Item 26: 26. The vaccine composition, lentiviral vector, lentiviral vector particle or cell according to item 25 for use according to item 25, wherein the at least one immune checkpoint inhibitor is administered simultaneously or separately, in particular wherein the at least one immune checkpoint inhibitor is administered at least 2 days, in particular at least 4 days, after administration of the vaccine composition, lentiviral vector, lentiviral vector particle or cell.

[0047] The details, examples, and preferred aspects provided in relation to any particular one or more of the described aspects of the invention are described further herein and apply equally to all aspects of the invention. Any combination in all possible variations of the embodiments, examples, and preferred aspects described herein are encompassed by the present invention unless otherwise indicated herein or clearly contradicted by context. [Brief description of the drawings]

[0048] [Figure 1]Figure 1 demonstrates that the HPV vaccine of the present invention is immunogenic in vivo. Mice were injected intramuscularly (im) with 1x107TU or 50 μL of dilutions of lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5759, the lentiviral vector deposited at the CNCM under accession number I-5760, the lentiviral vector deposited at the CNCM under accession number I-5761, or the lentiviral vector deposited at the CNCM under accession number I-5762. After 14 days, splenocytes were prepared and restimulated overnight for IFNg ELISPOT with four different peptide pools. Horizontal axis: from left to right: results obtained with the lentiviral vector deposited at the CNCM under accession number I-5759, the lentiviral vector deposited at the CNCM under accession number I-5760, the lentiviral vector deposited at the CNCM under accession number I-5761, the lentiviral vector deposited at the CNCM under accession number I-5762 or results obtained with 50 μL of diluent (control). Vertical axis: Spot forming cells (SFC) / 106 cells. [Diagram 2] FIG. 2 shows that the vaccine of the present invention successfully and completely eliminated transplanted tumors in vivo. TC-1 cells were injected subcutaneously (sc) and tumor volumes were measured every other day (caliper measurement). When the average tumor volume reached 70 mm3, mice were randomized and vaccinated with 1x108TU of LV-GFP Indiana (as control), Indiana lentiviral vector particles containing I-5759, Indiana lentiviral vector particles containing I-5760, Indiana lentiviral vector particles containing I-5761, or Indiana lentiviral vector particles containing I-5762 by intramuscular (im) injection. Horizontal axis: days. Vertical axis: tumor volume (mm3). [Diagram 3]Figure 3 shows the ability of lentiviral vectors according to the invention expressing designs I-5759, I-5760, I-5761, I-5762, or diluent as a control, to generate long-lasting immunity to prevent recurrence. Mice from which primary tumors were removed were rechallenged in the other flank on day 60. Subcutaneous (sc) injections were also performed in control mice (untreated) to confirm the growth of tumor cells in naive mice. Horizontal axis: days. Vertical axis: tumor volume (mm3). [Figure 4] Figure 4: Dose / response in mice. 1x106 TC-1 cells were injected into the flank of the animals and tumor volumes were measured twice weekly (caliper measurement). When the mean tumor volume was 80mm3, mice were randomized and vaccinated intramuscularly (im) with diluent (control), 1x107 TU of I-5759 vaccine or 1x108 TU of I-5759 vaccine. Horizontal axis: days. Vertical axis: tumor volume (mm3). [Diagram 5] FIG. 5 represents lymphocytic tumor infiltration after vaccination with lentiviral vectors according to the invention. 1×106 TC1 tumor cells were injected subcutaneously (sc) into the flank of the animals and tumor volumes were measured twice a week (caliper measurement). When the mean tumor volume was 80 mm3, mice were randomized and vaccinated intramuscularly (im) with diluent (control) or 1×107 TU of I-5759 vaccine or 1×108 TU of I-5759 vaccine. 10 days after vaccination, tumors were harvested, digested and analyzed by flow cytometry. FACS staining was performed and data were acquired on a Macsquant facs according to methods well known in the art. Horizontal axis: from left to right: diluent (control); 1×108 TU of I-5759 vaccine. Vertical axis: Top left: % CD8+ T cells (within live cells); Top right: % CD4+ T cells (within live cells); Bottom: % Treg cells (within live cells). [Figure 6]Figure 6 shows the ability of a vector according to the invention to eliminate large established tumors. 1x106 TC1 cells were injected subcutaneously (sc) into the flank of the animals. When the mean tumor volume was approximately 300 mm3, the mice were randomized and vaccinated intramuscularly (im) with 1x108 TU of a vaccine according to the invention comprising diluent (control) or lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759. Horizontal axis: days. Vertical axis: tumor volume (mm3). [Figure 7] Figure 7 shows T cell responses in human PBMCs labeled with CFSE and cultured in the absence (unstimulated) or presence of a vaccine according to the invention (I-5759). Cell proliferation and activation were measured after 2 weeks of culture (n=3). CD8+ and CD4+ T cell proliferation (measured by CFSE dilution) (A) and expression of the CD25 activation marker (B) were increased by adding lentiviral vectors of the invention to the cultures. Horizontal axis: from left to right: unstimulated (unstimulated-control); I-5759 vaccine. Vertical axis: (A) % of CFSElow in the CD8+ population; right panel: % of CFSElow in the CD4+ population. (B) Left panel: % of CD25+ in the CD4+ population; right panel: % of CD25+ in the CD8+ population. [Figure 8A] Figure 8A illustrates four examples of antigen constructs of lentiviral vectors according to the present invention. Each of these antigen constructs consists of four sequences in various orders: a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7. Figure 8A represents the antigen construct of lentiviral vectors deposited at the CNCM under the accession number I-5759. [Figure 8B]Figure 8B illustrates four examples of antigen constructs of lentiviral vectors according to the present invention. Each of these antigen constructs consists of four sequences in various orders: a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7. Figure 8B represents the antigen construct of lentiviral vectors deposited at the CNCM under the accession number I-5760. [Figure 8C] Figure 8C illustrates four examples of antigen constructs of lentiviral vectors according to the present invention. Each of these antigen constructs consists of four sequences in various orders: a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7. Figure 8C represents the antigen construct of lentiviral vectors deposited at the CNCM under the accession number I-5761. [Figure 8D] Figure 8D illustrates four examples of antigen constructs of lentiviral vectors according to the present invention. Each of these antigen constructs consists of four sequences in various orders: a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen, a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7. Figure 8D represents the antigen construct of lentiviral vectors deposited at the CNCM under the accession number I-5762. [Figure 9]FIG. 9 (FIG. 9A and FIG. 9B) illustrates the T cell cytokine response of spleen cells analyzed by intracellular cytokine staining with or without stimulation with a mixture of ETTDPDRAHYNIVTF (SEQ ID NO: 39) and PDRAHYNIVTFCCKC (SEQ ID NO: 40) synthetic peptides, where both synthetic peptides contain the RAHYNIVTF H-2Db-restricted T cell epitope (bold represents H-2Db anchor residues), and spleen cells were obtained 14 days after vaccination of C57BL / 6 mice (n=5 mice / group) immunized by intramuscular (im) injection with control Lenti (LV-GFP Indiana) or with a vaccine according to the present invention comprising lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759. FIG. 9A specifically depicts the cytometric gating strategy implemented on cytokine-producing CD8+ T cells and the degranulation activity of IFN-γ-producing CD8+ T cells assessed by surface CD107a staining. Figure 9B illustrates the T cell cytokine response of spleen cells analyzed by intracellular cytokine staining with or without stimulation with a mixture of ETTDPDRAHYNIVTF (SEQ ID NO: 39) and PDRAHYNIVTFCCKC (SEQ ID NO: 40) synthetic peptides, where both synthetic peptides contain the RAHYNIVTF H-2Db-restricted T cell epitope (bold represents H-2Db anchor residues), and spleen cells were obtained 14 days after vaccination of immunized C57BL / 6 mice (n=5 mice / group) with control Lenti (LV-GFP Indiana) or with a vaccine according to the invention comprising lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5759, by intramuscular (im) injection. Figure 9B illustrates the recapitulative frequencies of IFN-γ+CD107a+ cells within each (multi)functional cell subset and the CD8+T subset. [Figure 10]Figure 10 shows a cytometric analysis of tumor infiltrating innate immune cells (NK) in mice implanted with tumors and vaccinated with the HPV vaccine according to the invention (I-5759) or in mice implanted with tumors and not vaccinated (Control-Control Lenti). CD11b and NKp46 were detected. [Figure 11] Figure 11 represents the ability of the vector according to the invention to eliminate large established tumors. Rechallenge of cured mice (right panel) from which the primary tumor had been eliminated was performed with 1.106 TC-1 tumor cells implanted in the other flank 119 days after the first implantation and maintained without any treatment. To check the growth of tumor cells, control mice (untreated-control old mice-left panel) were also injected subcutaneously (sc). Horizontal axis: days after tumor rechallenge. Vertical axis: tumor volume (mm3). [Figure 12]Figure 12 (Figures 12A and 12B) shows the synergy between suboptimal vaccination with a vaccine according to the invention (I-5759) and anti-PD-1 therapy (anti-PD-1, a monoclonal antibody). Figure 12A represents the evolution of tumor volume (mm3 - vertical axis) over days (horizontal axis) after tumor implantation in mice (D0). The experiment was performed in three identical groups of mice implanted with tumors. In the first group (10 mice - control group - left panel of Figure 12A), the mice were administered LV-empty Indiana (D13) (as a control) (day indicated by the arrow) and then 4 days later anti-PD-1 (Programmed cell death protein-1) monoclonal antibody (D17, then D20, D22, D24, D28, and D31). In the second group (12 mice - control group - middle panel of Figure 12A), the mice were administered a vaccine according to the invention (I-5759) (D13) (day indicated by the arrow) and then 4 days later a control antibody (isotype control) (D17, then D20, D22, D24, D28 and D31). In the third group (14 mice - right panel of Figure 12A), the mice were administered a vaccine according to the invention (D13) (I-5759) (day indicated by the arrow) and then 4 days later a mAb anti-PD-1 (D17, then D20, D22, D24, D28 and D31). Figure 12B depicts the survival rate (% of mice - vertical axis) over time (days - horizontal axis) of mice in each group (control group 1: control Lenti + anti-PD-1; control group 2: I-5759 + control Ig; control group 3: I-5759 + anti-PD-1). [Figure 13]Figure 13 (Figures 13A and 13B) shows the cure of mice with lung metastases induced by intravenous injection of TC1-nLuc cells after a single infection with Lenti-HPV-07 vaccine. Figure 13A shows the change in luminescence values ​​expressed in photons per second (p / s) due to TC1-nLuc cells stably expressing nanoluciferase injected into different groups of mice over time (horizontal axis - days) after iv injection of TC1-nLuc cells in mice (vertical axis - total flux). Three groups of mice were tested:

[0049] (Figure 13 description continued) JPEG2024544566000001.jpg48170 Figure 13B represents the individual p / s values ​​for individual mice of the three experimental groups detailed above, 22 days after tumor injection. Vertical axis: luminescence values ​​(Total Flux) expressed as photons per second (p / s). Horizontal axis, from left to right: Negative group, Control group, Lenti group, Lenti-HPV-07 group.

[0050] Overview of Arrays SEQ ID NO:1 is a nucleic acid sequence encoding the E6 protein from HPV 16. SEQ ID NO:2 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:3 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:4 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:5 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:6 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:7 is the E6 protein amino acid sequence from HPV 16. SEQ ID NO:8 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV16. SEQ ID NO:9 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV16. SEQ ID NO:10 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:11 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 16. SEQ ID NO:12 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV16. SEQ ID NO:13 is a nucleic acid sequence encoding the E7 protein from HPV 16. SEQ ID NO:14 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 16. SEQ ID NO:15 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 16. SEQ ID NO:16 is the E7 protein amino acid sequence from HPV 16. SEQ ID NO:17 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 16. SEQ ID NO:18 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 16. SEQ ID NO:19 is a nucleic acid sequence encoding the E6 protein from HPV 18. SEQ ID NO:20 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:21 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:22 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:23 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:24 is the amino acid sequence of the E6 protein from HPV 18. SEQ ID NO:25 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:26 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:27 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:28 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. SEQ ID NO:29 is a nucleic acid sequence encoding the E7 protein from HPV 18. SEQ ID NO:30 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 18. SEQ ID NO:31 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 18. SEQ ID NO:32 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 18. SEQ ID NO:33 is the amino acid sequence of the E7 protein from HPV 18. SEQ ID NO:34 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 18. SEQ ID NO:35 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 18. SEQ ID NO:36 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 18. SEQ ID NO:37 is a nucleic acid sequence encoding the cPPT / CTS sequence. SEQ ID NO:38 is a nucleic acid sequence encoding a variant of the Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE). SEQ ID NO:39 is RAHYNIVTF H-2D b -Synthetic E7 containing restricted T cell epitopes HPV16 -derived peptide. SEQ ID NO:40 is RAHYNIVTF H-2D b -Synthetic E7 containing restricted T cell epitopes HPV16 -derived peptide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] The inventors have discovered that administering to an individual in need thereof a lentiviral vector encoding at least four different human papillomavirus (HPV) antigens, in particular at least four HPV antigens selected from among proteins E6 and E7 of at least two different HPV subtypes, in particular HPV16 subtype and HPV18 subtype, results in high prophylactic and therapeutic activity against HPV-induced cancers.

[0052] The lentiviral vector according to the invention can make it possible to induce a strong, sustained and broad cell-mediated response against tumors induced by HPV infection.

[0053] Lentiviral vectors according to the invention, as well as lentiviral vector particles comprising them, isolated cells comprising said lentiviral vectors or said lentiviral vector particles, and vaccine compositions comprising them, are described throughout this specification.

[0054] definition

[0055] All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified.

[0056] As used herein, "transgene" means a polynucleotide that can be expressed in a non-native environment or a heterologous cell under appropriate conditions via recombinant techniques.

[0057] As used herein, the term "recombinant" when used in connection with the cells of the invention indicates that the cells have been modified by introducing endogenous and / or heterologous nucleic acids or proteins into the cells or by modification of a native cell, or that the cells are derived from cells so modified. Thus, for example, recombinant cells express genes or nucleic acids not found in the native (non-recombinant) form of the cell, express native (e.g., endogenous) genes at levels different from their native levels, or express additional or supplemental copies of native (e.g., endogenous) genes at levels different from their native levels. An isolated cell according to the invention is recombinant in that it comprises at least one lentiviral vector according to the invention and / or at least one lentiviral vector particle according to the invention.

[0058] As used herein, the term "recombinant" when used in reference to a vector is a sequence formed / obtained by genetic engineering techniques well known to those skilled in the art.

[0059] As used herein, the term "polypeptide" refers to a molecule that contains amino acid residues linked by peptide bonds and contains more than five amino acid residues. Amino acids are identified by one-letter or three-letter designations. As used herein, the term "protein" is synonymous with the term "polypeptide" and may also refer to two or more polypeptides. Thus, the terms "protein", "peptide" and "polypeptide" may be used interchangeably. Polypeptides may be optionally modified (e.g., glycosylated, phosphorylated, acylated, farnesylated, prenylated, sulfonated, etc.) to add functionality. Polypeptides that exhibit activity may be referred to as enzymes. It will be understood that as a result of the degeneracy of the genetic code, numerous nucleotide sequences that code for a given polypeptide may be produced.

[0060] As used herein, the term "operably linked" refers to two or more nucleic acid sequence elements that are physically linked and in a functional relationship with each other. For example, in a lentiviral vector according to the present invention, a promoter is operably linked to a coding sequence, and since the promoter can initiate or regulate the transcription or expression of the antigen construct, it is also referred to herein as an "antigen construct", in which case the antigen construct should be understood as being "under the control" of the promoter. Generally, when two nucleic acid sequences are operably linked, they are in the same orientation, and also usually in the same reading frame. They are usually essentially contiguous, although this may not be required.

[0061] The term "encoding" or "coding for" refers to the process by which a polynucleotide produces an amino acid sequence through the mechanisms of transcription and translation.

[0062] For each amino acid sequence or amino acid sequence of interest, a reference sequence is described herein. The present specification also includes amino acid sequences that have a certain percentage of amino acid identity with the reference amino acid sequence.

[0063] For obvious reasons, throughout this specification, a specific nucleic acid sequence or a specific amino acid sequence that meets the nucleotide identity or amino acid identity, respectively, considered should further lead to obtaining a protein (or antigen) exhibiting the desired biological activity. As used herein, the "percentage of identity" between two nucleic acid sequences or two amino acid sequences is determined by comparing both optimally aligned sequences over a comparison window.

[0064] Thus, the portion of the nucleotide or amino acid sequence within the comparison window may contain additions or deletions (e.g., "gaps") compared to the reference sequence (which does not include these additions or these deletions) to obtain optimal alignment between both sequences.

[0065] The terms "sequence homology" or "sequence identity" or "homology" or "identity" are used interchangeably herein. For the purposes of the present invention, it is defined here that in order to determine the percentage of sequence homology or sequence identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes. To optimize the alignment between the two sequences, gaps may be introduced into either of the two sequences being compared. Such alignment can be performed over the entire length of the sequences being compared. Alternatively, the alignment can be performed over a shorter length, for example, about 20, about 50, about 100 or more nucleic acids / bases or amino acids. The sequence identity is the percentage of identical matches between the two sequences over the reported alignment region.

[0066] The comparison of sequences and the determination of the percentage of sequence identity between two sequences can be accomplished using a mathematical algorithm. Those skilled in the art will be aware of the fact that several different computer programs are available for aligning two sequences and determining the identity between the two sequences (Kruskal, JB (1983) An overview of sequence comparison In D. Sankoff and JB Kruskal, (ed.), Time warps, string edits and macromolecules: the theory and practice of sequence comparison, pp. 1-44 Addison Wesley).

[0067] The percent sequence identity between two amino acid sequences or two nucleotide sequences can be determined using the Needleman and Wunsch algorithm for aligning two sequences. (Needleman, SB and Wunsch, CD (1970) J. Mol. Biol. 48, 443-453). Both amino acid sequences and nucleotide sequences can be aligned by this algorithm. The Needleman-Wunsch algorithm is implemented in the computer program NEEDLE.

[0068] For the purposes of the present invention, the NEEDLE program from the EMBOSS package was used (version 2.8.0 or higher, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice, P. Longden J. and Bleasby, A. Trends in Genetics 16, (6) pp276-277, http: / / emboss.bioinformatics.nl / ). For protein sequences, the substitution matrix EBLOSUM62 was used. For base sequences, EDNAFULL was used. The optional parameters used are a gap opening penalty of 10 and a gap extension penalty of 0.5. No end gap penalty is added. In the output section, the question "Brief identity and similarity" is answered with "Yes" and "SRS pairwise" is shown as the Output alignment format.

[0069] After alignment with the program NEEDLE as described above, the percentage of sequence identity between the query sequence and the sequence of the invention is calculated as follows: the number of corresponding positions in the alignment that show identical amino acids or identical nucleotides in both sequences divided by the total length of the alignment after subtracting the total number of gaps in the alignment. Identity as defined herein can be obtained from NEEDLE by using the NOBRIEF option and is displayed as "longest-identity" in the program output.

[0070] Nucleotide and amino acid sequence similarity, i.e. percentage of sequence identity, can be determined using several other art-known algorithms, preferably using the mathematical algorithm of Karlin and Altschul (Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877), using hmmalign (HMMER package, http: / / hmmer.wustl.edu / ), or using the CLUSTAL algorithm (Thompson, JD, Higgins, DG & Gibson, TJ (1994) Nucleic Acids Res. 22, 4673-80), such as the CLUSTAL algorithm available at https: / / www.ebi.ac.uk / Tools / msa / clustalo / , or the GAP program (mathematical algorithm of University of Iowa), or the mathematical algorithm of Myers and Miller (1989-Cabios 4:11-17), or the Clone Manager program. 9. The preferred parameters used are the default parameters set out at https: / / www.ebi.ac.uk / Tools / msa / clustalo / .

[0071] The grade of sequence identity (sequence matching) can be calculated, for example, using BLAST, BLAT or BlastZ (or BlastX). A similar algorithm is incorporated in Altschul et al. (1990) J. Mol. Biol. 215, 403-410. BLAST polynucleotide searches are performed with the BLASTN program, score=100, wordlength=12, to obtain polynucleotide sequences homologous to nucleic acids encoding related proteins.

[0072] BLAST protein searches are performed with the BLASTP program, score=50, wordlength=3, to obtain amino acid sequences homologous to the SHC polypeptide. To obtain gapped alignments for comparison purposes, Gapped BLAST is used as described in Altschul et al. (1997) Nucleic Acids Res. 25, 3389-3402. When using BLAST and Gapped BLAST programs, the default parameters of the respective programs are used. Sequence matching analysis can be supplemented by established homology mapping techniques such as Shuffle-LAGAN (Brudno M., Bioinformatics 2003b, 19 Suppl 1:154-162) or Markov random fields. When percentages of sequence identity are referred to in this application, these percentages are calculated relative to the full length of the longer sequence, unless otherwise indicated.

[0073] In certain embodiments, the percent identity between two sequences is determined using CLUSTAL O (version 1.2.4).

[0074] The term "non-oncogenic" as used herein is used in its traditional sense, i.e., referring to an element, in this case an antigen, that is not capable of causing the formation of a tumor. As detailed elsewhere, the antigens embodied in the present invention have been genetically modified to be non-oncogenic. According to the normal meaning of these terms, it means that the nucleic acid sequences encoding the antigens embodied herein do not occur in nature and have been altered, either by introduction or by deletion or by modification of those nucleic acid sequences, resulting in an encoded amino acid sequence that also does not occur in nature.

[0075] Those skilled in the art have long been aware of the various means for making deletions, substitutions or introductions in nucleic acid sequences.

[0076] As will be appreciated by those skilled in the art, it may be further advantageous to modify the coding sequence to enhance its expression in a particular host. Although the genetic code is redundant with 64 possible codons, most organisms typically use a subset of these codons. The most frequently used codons in a species are called optimal codons, and the less frequently used codons are classified as rare or low-usage codons. Codons can be substituted to reflect the host's preferred codon usage, in a process also called "codon optimization" or "controlling for species codon bias." Codon optimization for other host cells can be easily determined using codon usage tables or can be performed using commercially available software, such as CodonOp from Integrated DNA Technologies (www.idtdna.com / CodonOptfrom). Optimized coding sequences containing codons preferred by a particular prokaryotic or eukaryotic host (Murray et al, 1989, Nucl Acids Res. 17:477-508) can be prepared, for example, to increase the translation rate or to produce recombinant RNA transcripts with desirable properties, such as longer half-life, compared to transcripts produced from non-optimized sequences. Translation stop codons can also be modified to reflect host preferences. For example, the typical stop codon for monocotyledonous plants is UGA, while insects and E. coli commonly use UAA as the stop codon (Dalphin et al, 1996, Nucl Acids Res. 24:216-8).

[0077] "Non-integrative" lentiviral vector means that the lentiviral vector does not integrate into the host cell genome when the lentiviral vector is in the cell. Non-integrative lentiviral vector particle refers to a lentiviral vector particle that comprises a non-integrative lentiviral vector. Non-integrative lentiviral vectors are also called integration-defective lentiviral vectors or non-integrating lentiviral vectors.

[0078] HPV-induced cancer is also known as cancer associated with HPV (Human Papillomavirus). In fact, HPV infection is not well controlled by the immune system of the infected host. If a high-risk HPV infection continues for many years, it can cause cellular changes that, if not treated, can worsen over time and turn into cancer.

[0079] Lentiviral vectors according to the invention

[0080] The present inventors have devised a novel therapeutic and prophylactic lentiviral vector-based vaccine against HPV-induced cancers.

[0081] In particular, the present invention relates to lentiviral vectors comprising at least four different nucleic acid sequences selected from a group of specific non-oncogenic HPV antigens.

[0082] By different nucleic acid sequences it is meant that at least four nucleic acid sequences contained in the lentiviral vector are all different, i.e., each of the nucleic acid sequences is a different member of a group of specific non-oncogenic HPV antigens.

[0083] The group of non-oncogenic HPV antigens is: a nucleic acid sequence encoding the non-oncogenic human papillomavirus 16 (HPV16) protein E6 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen; A nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen; and A nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen.

[0084] Unlike most HPV proteins that disappear after HPV integration, E6 and E7 proteins are continuously expressed in HPV-induced tumors (Ghittoni,Raffaella et al. Virus genes vol. 40,1 (2010):1-13; Morrow,Matthew P et al. Expert review of vaccines vol. 12,3 (2013):271-83). These proteins are known to inhibit cell functions and play an important role in HPV-associated carcinogenesis. (Tomaic,Vjekoslav.Cancers vol.8,10 95.19 Oct. 2016; Ghittoni,Raffaella et al. Virus genes vol. 40,1 (2010):1-13). E6 and E7 are thought to interfere with multiple pathways, but most importantly, expression of E6 protein in cells leads to ubiquitin-mediated degradation of the tumor suppressor p53 by direct interaction with the intracellular E3 ubiquitin ligase E6AP (Huibregtse,JM et al:4129-35; Martinez-Zapien,Denise et al. Nature 529,7587 (2016):541-5), and E7 binds to Rb protein, thereby disrupting the interaction of Rb with E2F and releasing E2F factors (Cassetti,M Cristina et al:520-7).

[0085] Since E6 and E7 proteins are expressed in all HPV-induced cancers, it was decided to include antigens from these proteins for the two major subtypes (HPV16 and HPV18) in the lentiviral vector of the present invention. In order to develop a vaccine from E6 and E7 antigens, it is important to eliminate the carcinogenic risk associated with these proteins.

[0086] Non-oncogenic E6 and E7 proteins are thus implemented in the present invention. "Non-oncogenic E6 and E7 HPV proteins" means that their coding sequences are modified to remove p53, Mi2b and Rb binding sites and PDZ binding motifs.In a particular embodiment, partial mutation of E6 and E7 HPV protein binding sites cannot completely eliminate Rb binding, so these sites are particularly completely removed from the sequences implemented in the present invention.

[0087] The lentiviral vector according to the invention may be single-stranded or double-stranded. The lentiviral vector according to the invention may be an RNA or a DNA molecule.

[0088] In the context of the present invention, a "lentiviral vector" refers to a non-replicating vector for introducing transgenes into a host cell that contain cis-acting lentiviral RNA or DNA sequences and require essential lentiviral proteins (e.g., Gag, Pol and / or Env) and accessory proteins (e.g., Tat, Rev) provided in trans. The lentiviral vector lacks the expression of all functional HIV proteins. The genome of the lentiviral vector can be in the form of an RNA or DNA molecule, depending on the stage of production or development of the retroviral vector.

[0089] In a preferred embodiment, the lentiviral vector of the present invention is a non-integrative lentiviral vector.

[0090] Non-integrating lentiviral vectors have been designed to reduce the potential risk of oncogenesis associated with insertional mutagenesis events, especially for vaccination purposes. Examples of non-integrating lentiviral vectors are provided in Coutant et al., PLOS ONE 7(11):e48644 (2012), Karwacz et al., J. Virol. 83(7):3094-3103 (2009), Negri et al., Molecular Therapy 15(9):1716-1723 (2007); and Hu et al., Vaccine 28:6675-6683 (2010). As a result, it has been reported that non-integrating lentiviral vector systems can reduce the potential risk of insertional mutagenesis compared to integrating systems (Hu et al., Vaccine 28:6675-6683(2010)). It has also been reported that the magnitude and quality of immune responses elicited by DC-directed integration-defective lentiviral vectors (IDLVs) are comparable to those of the integrative vectors in several functional studies. Therefore, IDLVs have been considered to be safer than integrative vectors and to have comparable efficacy when administered to humans.

[0091] In addition, the deletion of the U3 region of the 3'LTR of the viral promoter and enhancer sequences in self-inactivating lentiviral vectors limits the possibility of endogenous promoter activation. These safety concerns are directly related to the experience gained from the SCID-X1 gene therapy trial conducted in 1998-1999, which was conducted using Moloney virus-based retroviral vectors in children with a rare form of X-linked (SCID-X1 gene) severe immunodeficiency disease (Cavazzana-Calvo et al., 2000, Science., 288 (5466): 669-72). During this trial, four of the nine children developed leukemia as a result of integration of the Moloney-derived retroviral vector close to the human LM02 proto-oncogene (Hacein-Bey-Abina et al., 2008, J. Clin. Invest., 118(9):3132-3142). It was demonstrated that malignancy was the result of close proximity of the viral U3 promoter / enhancer to the LM02 proto-oncogene. As a result, safety is a major concern for administration of lentivectors to humans.

[0092] Thus, a lentiviral vector according to the invention may contain long terminal repeat (LTR) sequences in cis, as known in the art, and in particular a 3' long terminal repeat (LTR) lacking its U3 promoter sequence (Miyoshi H et al, 1998, J Virol. 72(10):81 50-7; Zufferey et al., 1998, JV / ro / 72(12):9873-80).

[0093] Enhancers are cis-acting sequences that can act as transcriptional activators at a distance. Enhancer sequences have been widely adopted in virus-derived vectors because they are considered to be the most efficient in obtaining strong expression of transgenes in various cell types, especially DCs (Chinnasamy et al., 2000, Hum Gene Ther 11(13):1901-9; Rouas et al., 2008, Cancer Gene Ther 9(9):715-24; Kimura et al., 2007, Mol Ther 15(7):1390-9; Gruh et al., 2008, J Gene Med 10(1) 21-32). However, considering the safety issue of insertional mutagenesis, such transcriptional enhancer sequences should be deleted from lentiviral vector constructs to eliminate the risk of insertional mutagenesis due to enhancer proximity effect. This enhancer proximity effect is the most frequent mechanism of insertional mutagenesis and the only effect described in human or animal cases of tumorigenic events following gene transfer.

[0094] Thus, a lentiviral vector according to the present invention may not contain a constitutive enhancer sequence.

[0095] Previous studies have reported replacing viral promoters with DC-specific promoters derived from major histocompatibility complex class II genes (MHC class II) and dectin-2 genes (Lopes et al., 2008, J Virol 82(1):86-95) (Kimura et al., 2007, Mol Ther 15(7):1390-9). The dectin-2 gene promoter used by Lopes et al. contains a putative enhancer and an adenoviral conserved sequence (an inverted terminal repeat in adenoviral promoters) (Bonkabara et al., 2001, J. Immunology, 167:6893-6900). The MHC class II gene promoter used by Kimura et al. does not contain any known enhancer.

[0096] However, without an enhancer, the MHC class II promoter was found to not provide sufficient transgene expression in DCs when administered intravenously. Notably, lentiviral vectors containing the MHC class II promoter did not elicit an immune response in immunocompetent C57BL / 6 mice, in contrast to the immune response observed with the CMV promoter / enhancer. Although integration and persistent transgene expression were observed after injection into mice, lentiviral vectors transcribed via the MHC class II promoter did not elicit antigen-specific CD8+ cells, even after a vaccination boost. + The MHC class II promoters failed to stimulate a cytotoxic T lymphocyte response. Therefore, the authors of these studies concluded that the use of MHC class II promoters is only of interest for applications requiring sustained expression, such as gene replacement therapy, and not in the context of immunotherapy. Of note, MHC class II promoters are poorly expressed in most cell types.

[0097] Therefore, the MHC class II promoter is not suitable as a promoter of lentiviral vectors for inducing immune responses to antigens by intravenous (IV) injection. Moreover, the dectin-2 promoter is poorly expressed in most cell types and appears to contain an enhancer. Therefore, the dectin-2 promoter is not a good promoter for lentiviral vectors for safety reasons.

[0098] Thus, a lentiviral vector according to the invention may comprise an MHC class I promoter, i.e. the nucleic acid sequence encoding the antigen of the lentiviral vector according to the invention may be under the control of an MHC class I promoter.

[0099] Suitable MHC class I promoters may be selected from the group consisting of the β2-microglobulin promoter, the HLA-A2 promoter, the HLA-B7 promoter, the HLA-Cw5 promoter, the HLA-E promoter or the HLA-F promoter, more particularly the β2-microglobulin promoter.

[0100] MHC class I promoters are dendritic-specific (APC), with promoter expression in BDCA+ dendritic cells being higher than in kidney, smooth muscle, liver, and heart cells. Other transduced cell types show relatively high expression, e.g., promoter expression in BDCA+ dendritic cells is only 12-100-fold higher than that of skeletal muscle cells, whereas the MHCII HLA-DRα promoter is 900-fold higher.

[0101] This promoter specifically drives the transcription of the nucleic acid sequence encoding the HPV antigen in the lentiviral vector of the invention.

[0102] The promoter may be a naturally occurring MHC class I promoter or a synthetic MHC class I promoter obtained using well known molecular biology techniques.

[0103] A lentiviral vector according to the invention may comprise a cPPT / CTS sequence as described in European Patent EP 2169073. This cPPT / CTS sequence may in particular be the sequence described as nucleic acid sequence SEQ ID NO:37.

[0104] In fact, efficient integration and replication in non-dividing cells generally requires the presence of two cis-acting sequences in the center of the lentiviral genome, the central polypurine tract (cPPT) and the central termination sequence (CTS), which result in the formation of a triple-stranded DNA structure called the central DNA "flap," which acts as a signal for the uncoating of the pre-integration complex at the nuclear pore and allows efficient uptake of the expression cassette into the nuclei of non-dividing cells, e.g., dendritic cells.

[0105] The lentiviral vectors of the present invention may contain a Woodchuck Hepatitis B Virus (WHV) Post-Transcriptional Regulatory Element (WPRE), which allows for more stable expression of the transgene in vivo, particularly a variant of the Woodchuck Hepatitis B Virus (WHV) Post-Transcriptional Regulatory Element (WPRE).

[0106] The mutated Woodchuck Posttranscriptional Regulatory Element (mWPRE) has been characterized in that a point mutation has been introduced to prevent expression of the X protein contained in the WPRE region, which may have oncogenic properties (Kingsman et al. 2005 Jan;12(1):3-4).

[0107] The mutated Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE) contained in the lentiviral vector of the present invention may in particular have the nucleic acid sequence set forth as nucleic acid sequence SEQ ID NO:38.

[0108] In a particular embodiment, the lentiviral vector according to the invention, in particular the non-integrating lentiviral vector of the invention, comprises: (i) at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E6 antigen, at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E7 antigen, at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E6 antigen, and at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E7 antigen; (ii) contains a 3' long terminal repeat (LTR) that lacks a U3 promoter sequence; (iii) does not contain a constitutive enhancer sequence; (iv) an MHC class I promoter, in particular the β2-microglobulin promoter; (v) a cPPT / CTS sequence, in particular the PPT / CTS sequence set forth as nucleic acid sequence SEQ ID NO:37; and (vi) A variant of the Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE), particularly the variant having the nucleic acid sequence set forth as nucleic acid sequence SEQ ID NO:38.

[0109] As mentioned above, the lentiviral vector according to the invention is characterized in that it comprises: At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen, At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen, At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and At least one nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen.

[0110] At least four nucleic acid sequences, in particular four different nucleic acid sequences, encoding HPV antigens of the lentiviral vector of the present invention may in particular be fused together and under the control of a single promoter sequence to form a single antigen nucleic acid sequence encoding a single antigen fusion protein, in particular when (i) there is no linking sequence (also referred to herein as a spacer) between each of said at least four different nucleic acid sequences, or (ii) there is a linking sequence (or spacer) between at least two of said at least four different nucleic acid sequences, more in particular when there is a linking sequence (or spacer) between each of said at least four different nucleic acid sequences.

[0111] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E6 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 80% sequence identity with the amino acid sequence set forth as SEQ ID NO:7.

[0112] As described herein, an amino acid sequence having at least 80% amino acid identity with a reference amino acid sequence includes amino acid sequences having at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% amino acid identity with the reference amino acid sequence.

[0113] In particular, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E6 antigen may have a nucleic acid sequence having at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

[0114] As described herein, a nucleic acid sequence having at least 80% nucleotide identity to a reference nucleic acid sequence includes nucleic acid sequences having at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% nucleotide identity to the reference nucleic acid sequence.

[0115] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E6 antigen may in particular have a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

[0116] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E6 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12.

[0117] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E6 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12.

[0118] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E7 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 68% sequence identity with the amino acid sequence set forth as SEQ ID NO:16.

[0119] As described herein, an amino acid sequence having at least 68% amino acid identity to a reference amino acid sequence includes amino acid sequences having at least 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% amino acid identity to the reference amino acid sequence.

[0120] In particular, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E7 antigen may have a nucleic acid sequence having at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:14 and SEQ ID NO:15.

[0121] As described herein, a nucleic acid sequence having at least 80% nucleotide identity to a reference nucleic acid sequence includes nucleic acid sequences having at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% nucleotide identity to the reference nucleic acid sequence.

[0122] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E7 antigen may in particular have a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:14 and SEQ ID NO:15.

[0123] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E7 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:17 and SEQ ID NO:18.

[0124] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 16 (HPV16) protein E7 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:17 and SEQ ID NO:18.

[0125] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E6 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 60% sequence identity with the amino acid sequence set forth as SEQ ID NO:24.

[0126] As described herein, an amino acid sequence having at least 60% amino acid identity to a reference amino acid sequence includes an amino acid sequence having at least 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% amino acid identity to the reference nucleic acid sequence.

[0127] In particular, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E6 antigen may have a nucleic acid sequence having at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

[0128] As described herein, a nucleic acid sequence having at least 80% nucleotide identity to a reference nucleic acid sequence includes nucleic acid sequences having at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% nucleotide identity to the reference nucleic acid sequence.

[0129] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E6 antigen may in particular have a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

[0130] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E6 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28.

[0131] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E6 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28.

[0132] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E7 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 83% sequence identity with the amino acid sequence set forth as SEQ ID NO:33.

[0133] As described herein, an amino acid sequence having at least 83% amino acid identity with a reference amino acid sequence includes amino acid sequences having at least 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% amino acid identity with the reference amino acid sequence.

[0134] In particular, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E7 antigen may have a nucleic acid sequence having at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.

[0135] As described herein, a nucleic acid sequence having at least 80% nucleotide identity to a reference nucleic acid sequence includes nucleic acid sequences having at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% nucleotide identity to the reference nucleic acid sequence.

[0136] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E7 antigen may in particular have a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.

[0137] The nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E7 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36.

[0138] In certain embodiments, the nucleic acid sequence encoding the non-oncogenic Human Papillomavirus 18 (HPV18) protein E7 antigen may in particular have a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of the amino acid sequences set forth as SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36.

[0139] As indicated above, the lentiviral vector according to the invention comprises: at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen (herein designated noE6-HPV16); at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen (herein designated noE7-HPV16); At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen (herein designated noE6-HPV18), and At least one nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen (herein designated noE7-HPV18).

[0140] In a particular embodiment, the lentiviral vector according to the invention, in particular the non-integrating lentiviral vector of the invention, comprises: (i) a nucleic acid sequence encoding a non-oncogenic human papillomavirus 16 (HPV 16) protein E6 antigen; a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E7 antigen; a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E6 antigen; and a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E7 antigen; wherein multiple nucleic acid sequences encoding non-oncogenic HPV antigens are particularly fused together to form a single antigen nucleic acid sequence encoding a single antigen fusion protein under the control of a single promoter sequence, more particularly when there are no linking sequences between each of the multiple nucleic acid sequences; (ii) containing a 3′ long terminal repeat (LTR) lacking the U3 promoter sequence; (iii) does not contain a constitutive enhancer sequence; (iv) an MHC class I promoter, in particular the β2-microglobulin promoter; (v) comprises a cPPT / CTS sequence, particularly the cPPT / CTS sequence set forth as nucleic acid sequence SEQ ID NO:37; and (vi) A variant of the Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE), particularly the variant having the nucleic acid sequence set forth as nucleic acid sequence SEQ ID NO:38.

[0141] A lentiviral vector according to the invention may more particularly comprise: at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen, wherein said nucleic acid sequence has at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, in particular the nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen, wherein said nucleic acid sequence has at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:14 and SEQ ID NO:15, in particular the nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:14 and SEQ ID NO:15; At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen, wherein said nucleic acid sequence has at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23, in particular the nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23; and at least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen, wherein said nucleic acid sequence has at least 80% sequence identity with a nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32, in particular the nucleic acid sequence selected from the group consisting of the nucleic acid sequences set forth as SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32; Here, multiple nucleic acid sequences encoding non-oncogenic HPV antigens are particularly fused together under the control of a single promoter sequence, more particularly when there are no linking sequences between each of the multiple nucleic acid sequences, to form a single antigen nucleic acid sequence encoding a single antigen fusion protein.

[0142] The at least four, in particular four different nucleic acid sequences encoding HPV antigens in a lentiviral vector according to the invention, in particular a non-integrating lentiviral vector of the invention, can be in any order in the conventional 5' to 3' reading direction (from the 5' end to the 3' end).

[0143] In particular, the four different nucleic acid sequences encoding the above defined HPV antigens noE6-HPV16, noE7-HPV16, noE6-HPV18 and noE7-HPV18 may be in any order, in the conventional 5' to 3' reading direction, among the 24 possible combinations in a lentiviral vector according to the invention, in particular in a non-integrating lentiviral vector according to the invention.

[0144] In certain embodiments, the order from the 5' to the 3' end of the at least four different nucleic acid sequences is selected from the group consisting of: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen; (b) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen; (c) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen; and (d) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen; Here, multiple nucleic acid sequences encoding non-oncogenic HPV antigens are particularly fused together under the control of a single promoter sequence, more particularly when there are no linking sequences between each of the multiple nucleic acid sequences, to form a single antigen nucleic acid sequence encoding a single antigen fusion protein.

[0145] These sequences are illustrated in Figures 8A-8D.

[0146] The order from the 5' to the 3' end of the at least four different nucleic acid sequences in a lentiviral vector according to the invention may more particularly be as follows: (d) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen; Here, multiple nucleic acid sequences encoding non-oncogenic HPV antigens are particularly fused together under the control of a single promoter sequence, more particularly when there are no linking sequences between each of the multiple nucleic acid sequences, to form a single antigen nucleic acid sequence encoding a single antigen fusion protein.

[0147] Preferably, the order from the 5' to the 3' end of the at least four different nucleic acid sequences in a lentiviral vector according to the invention is as follows: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen; Here, multiple nucleic acid sequences encoding non-oncogenic HPV antigens are particularly fused together under the control of a single promoter sequence, more particularly when there are no linking sequences between each of the multiple nucleic acid sequences, to form a single antigen nucleic acid sequence encoding a single antigen fusion protein.

[0148] More preferably, the order from the 5' to the 3' end of the at least four different nucleic acid sequences in a lentiviral vector according to the invention is as follows: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen-a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen; Here, multiple nucleic acid sequences encoding non-oncogenic HPV antigens are fused together and under the control of a single promoter sequence, forming a single antigen nucleic acid sequence encoding a single antigen fusion protein, when there are no linking sequences between each of the multiple nucleic acid sequences.

[0149] Each of these four different groups of antigen constructs is embodied in the present example: The lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) on October 21, 2021 under accession number I-5759 (order (a) above); the lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) on October 21, 2021 under accession number I-5760 (order (b) above); the lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) under accession number I-5761 on October 21, 2021 (order (c) above); or Lentiviral vector (order (d) above) deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) on October 21, 2021 under accession number I-5762.

[0150] Thus, the lentiviral vector antigen construct deposited at the CNCM under the accession number I-5759 has the following nucleotide sequence, set forth as SEQ ID NO:41: and encodes the following amino acid sequence, set forth as SEQ ID NO:42: MPGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIASQAFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRSAGPGPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWVGEPGRTIPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGH (SEQ ID NO: 42)

[0151] The lentiviral vector antigen construct deposited at the CNCM under the accession number I-5760 has the following nucleotide sequence, set forth as SEQ ID NO: 43: and encodes the following amino acid sequence, set forth as SEQ ID NO:44: MFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRGPDDPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGPGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIGPDDKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWA (SEQ ID NO: 44)

[0152] The lentiviral vector antigen construct deposited at the CNCM under the accession number I-5761 has the following nucleotide sequence, set forth as SEQ ID NO: 45: and encodes the following amino acid sequence, set forth as SEQ ID NO:46: MRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGHFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRSAGPGPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWAGPGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIA (SEQ ID NO: 46)

[0153] The lentiviral vector antigen construct deposited at the CNCM under the accession number I-5762 has the following nucleotide sequence, set forth as SEQ ID NO:47: and encodes the following amino acid sequence, set forth as SEQ ID NO:48: MGPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPGEPGRTIPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGPGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIASQAFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRS (SEQ ID NO:48).

[0154] A lentiviral vector according to the invention may in particular comprise a nucleic acid sequence encoding an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth as SEQ ID NO:42, wherein this nucleic acid sequence is in particular the nucleic acid sequence SEQ ID NO:41.

[0155] As described herein, an amino acid sequence having at least 90% identity to a reference amino acid sequence includes amino acid sequences having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and 100% identity to the reference amino acid sequence.

[0156] Thus, the lentiviral vector according to the invention may more particularly be selected from the group consisting of the lentiviral vectors deposited at the CNCM under accession number I-5759, accession number I-5760, accession number I-5761 and accession number I-5762, in particular the lentiviral vector deposited at the CNCM under accession number I-5762. The lentiviral vector according to the invention may preferably be the lentiviral vector deposited at the CNCM under accession number I-5759, and therefore preferably comprises the nucleic acid sequence SEQ ID NO: 41.

[0157] Lentiviral vector particles according to the invention

[0158] Another object of the invention relates to a lentiviral vector particle comprising at least one lentiviral vector according to the invention, in particular at least one lentiviral vector as defined above.

[0159] A lentiviral vector particle according to the invention comprises a lentiviral vector according to the invention and can be produced by recombinant techniques known in the art upon transient transfection of cells, e.g. HEK 293T human cultured cells, with different DNA plasmids: (i) a packaging plasmid, which expresses at least Gag, Pol, Rev, Tat, and optionally the structural and enzymatic proteins required for packaging of the transfer construct; (ii) a lentiviral vector according to the invention, which comprises an expression cassette (antigen) and HIV cis-acting factors necessary for packaging, reverse transcription and integration; and (iii) Plasmids encoding an envelope, most often the glycoprotein of vesicular stomatitis virus (VSV.G), which allows the formation of mixed particles (pseudotypes) that can target a wide variety of cells, in particular major histocompatibility (MHC) antigen-presenting cells (APCs), including DCs.

[0160] Such a method can be used to produce a recombinant vector particle according to the invention, the method comprising: i) transducing a suitable host cell with a lentiviral vector according to the invention; ii) transducing said host cells with a packaging plasmid vector comprising viral DNA sequences encoding at least the structural and polymerase activities of a retrovirus, preferably a lentivirus, where such packaging plasmids have been described, for example, in the art (Dull et al., 1998, J Virol, 72(11):8463-71; Zufferey et al., 1998, J Virol 72(12):9873-80); iii) culturing the transfected host cells to obtain expression of the lentiviral vector and packaging into lentiviral vector particles; and iv) harvesting the lentiviral vector particles resulting from expression and packaging of step iii) in the cultured host cells. The process includes the steps of:

[0161] To pseudotype the retroviral particles of the invention, the host cell can further be transfected with one or several envelope DNA plasmids encoding one or more viral envelope proteins, preferably the VSV-G envelope protein.

[0162] This procedure can obtain the transient production of lentiviral particle vector by transfected cells. However, by stably inserting packaging genes, provirus-encoding DNA and envelope genes into the cell genome, lentiviral particle vector can also be continuously produced by the cell. This allows the continuous production of lentiviral particle vector by the cell without the need for transient transfection. Of course, a combination of these procedures can be used, where some of the DNA / plasmid is integrated into the cell genome and others are provided by transient transfection.

[0163] The lentiviral vector particle may be a non-integrating lentiviral vector particle. The non-integrating vector particle has one or more mutations that eliminate most or all of the integrating capacity of the lentiviral vector particle. For example, the non-integrating vector particle can include one or more mutations in the integrase encoded by the lentiviral pol gene that result in a reduction in the integrating capacity.

[0164] Lentiviral vector particles according to the invention in particular include non-integrative lentiviral vectors of the invention.

[0165] Lentiviral vector particles according to the invention may comprise vesicular stomatitis virus glycoprotein (VSVG), in particular VSV-G Indiana serotype or VSV-G New Jersey serotype.

[0166] Regarding vaccination strategies, pseudotyped lentiviral vector particles have a high potential to evade the immune system if it has already acquired immunity to lentiviruses, which is particularly useful when serial injections of the same particle vector are required to immunize patients against a disease.

[0167] The lentiviral vector particle may comprise HIV-1 Gag and Pol proteins, in particular HIV-1 subtype D Gag and Pol proteins.

[0168] A further object of the present invention relates to an isolated cell comprising a lentiviral vector according to the invention or a lentiviral vector particle of the invention (i.e. transformed with a lentiviral vector according to the invention or a lentiviral vector particle of the invention).

[0169] The cells according to the invention are preferably mammalian cells, in particular human cells, particularly preferred are human non-dividing cells.

[0170] Another object of the invention relates to a vaccine composition comprising a lentiviral vector according to the invention, a lentiviral vector particle according to the invention or a cell according to the invention.

[0171] The vaccine composition according to the invention comprises a pharma- ceutically acceptable vehicle.

[0172] "Pharmaceutically acceptable vehicle" refers to any solution used to solubilize and deliver to an individual a lentiviral vector, lentiviral vector particle, or cell according to the present invention. A preferred pharmaceutically acceptable carrier is saline. In a preferred embodiment, the pharmaceutically acceptable vehicle includes an adjuvant.

[0173] Suitable physiologically acceptable vehicles and their formulations are known to those skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences, (20th edition), ed. A. Gennaro, 2003, Lippincott Williams & Wilkins.

[0174] Implementation in accordance with the present invention

[0175] An object of the present invention relates to a lentiviral vector according to the invention, a lentiviral vector particle according to the invention or an isolated cell according to the invention for use as a medicament or a vaccine.

[0176] In particular, the object of the present invention relates to a lentiviral vector of the invention, to a lentiviral vector particle of the invention or to an isolated cell of the invention, in particular in the form of a vaccine composition according to the invention, for use in the treatment or prevention of HPV-induced cancers and their metastases, in particular HPV-induced cancers.

[0177] As previously indicated, HPV-induced cancers are cancers induced by infection with HPV. Methods for the detection of HPV in cancers are known in the art (Aldo Venuti and Francesca Paolini; Head Neck Pathol. 2012 Jul; 6(Suppl 1):63-74).

[0178] The HPV-induced cancer may in particular be selected from the group consisting of cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer and oropharyngeal cancer.

[0179] Such cancer metastases according to the present invention may in particular be lung metastases.

[0180] Such prevention and / or treatment means the administration of the considered active, in particular the vaccine composition of the invention as defined above, to an individual in need of such prevention and / or treatment.

[0181] Individuals in need of such prevention and / or treatment are animals, particularly mammals, and especially humans.

[0182] The lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the present invention are administered to individuals in need of such prevention and / or treatment by conventional methods in dosages sufficient to elicit an immunological response that can be readily determined by one of skill in the art.

[0183] Thus, lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the invention may be administered intravenously or intramuscularly as indicated below.

[0184] Alternatively, the lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the invention may be administered intranasally, which route of administration is particularly useful in the treatment or prevention of oropharyngeal carcinoma and / or lung metastases.

[0185] The lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the invention are administered in a therapeutically effective amount, in particular at least 1×10 6 , 2×10 6 , 5×10 6 , 1×10 7 , 2×10 7 , 5×10 7 , 1×10 8 , 2×10 8 , 5×10 8 or at least 1 x 10 of a lentiviral vector according to the invention. 9 In particular, at least 1 x 10 of the lentiviral vector according to the invention, in a dose corresponding to TU (Transduction units). 7, 2×10 7 , 5×10 7 , 1×10 8 TU or at least 1×10 9 In a preferred embodiment, the lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the invention are administered in a dose equivalent to 1×10 6 TU of the lentiviral vector according to the invention. 7 TU, more particularly at least 1×10 8 TU, in particular at least 1×10 9 It is administered in a dose equivalent to TU.

[0186] A "therapeutically effective amount" refers, for example, to the amount of a lentiviral vector or lentiviral vector particle, cell, or vaccine composition according to the invention that is necessary to produce one or more of the following effects in a subject: an immune response against HPV-induced tumors; a reduction in the size of HPV-induced tumors, i.e., at least a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in tumor size in 15-45 days compared to the tumor size at the time of administration; an increase in CD8+ expression in HPV-induced tumors in 5-45 days after administration; + and / or CD4 + Increase in invasion; CD25 in HPV-induced tumors 5–45 days after administration + FoxP3 + CD4 + Decrease in regulatory T cells (Tregs).

[0187] Administration can be carried out using well-known routes, such as those mentioned above, including intravenous, intramuscular, intranasal, intraperitoneal or subcutaneous injection, and in particular may be intravenous, intranasal or intramuscular, and may be intravenous or intramuscular.

[0188] It will be apparent that appropriate dosages and regimens will vary between species and individuals depending on many factors, for example, higher doses will generally be required to obtain an effective immune response in humans compared to mice.

[0189] The lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the invention can be administered in a single dose or in two or more doses, for example as illustrated in the examples. The skilled person will determine in each case the appropriate regimen and dosage for the administration of the active ingredients according to the invention.

[0190] The lentiviral vectors, lentiviral vector particles, cells and vaccine compositions according to the invention may advantageously be administered in combination with at least one immune checkpoint inhibitor (ICI).

[0191] The immune checkpoint inhibitor (ICI) according to the invention may in particular be an antibody, in particular an anti-PD-1 antibody, an anti-PD-L1 (PD-1 ligand) antibody, an anti-CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) antibody, an anti-NKG2A antibody, an anti-TIM-3 (T cell immunoglobulin and mucin domain containing-3) antibody, an anti-TIGIT (T cell immunoreceptor having an Ig domain and an ITIM domain) antibody or an anti-LAG-3 (lymphocyte activation gene 3) antibody. More in particular, the at least one immune checkpoint inhibitor according to the invention may be a monoclonal antibody selected from the group consisting of an anti-PD-1 monoclonal antibody, an anti-PD-L1 monoclonal antibody, an anti-CTLA-4 monoclonal antibody, an anti-NKG2A monoclonal antibody, an anti-TIM-3 monoclonal antibody, an anti-TIGIT monoclonal antibody and an anti-LAG-3 monoclonal antibody. Even more particularly, the at least one immune checkpoint inhibitor according to the present invention may be a monoclonal antibody selected from the group consisting of an anti-PD-1 monoclonal antibody, an anti-PD-L1 monoclonal antibody, an anti-CTLA-4 monoclonal antibody, an anti-NKG2A monoclonal antibody, an anti-TIM-3 monoclonal antibody, and an anti-TIGIT monoclonal antibody.

[0192] Immune checkpoint inhibitors (ICI) according to the invention are more particularly antibodies, in particular anti-PD-1 antibodies, anti-PD-L1 (PD-1 ligand) antibodies, anti-CTLA-4 (cytotoxic T lymphocyte associated protein 4) antibodies, anti-NKG2A antibodies, anti-TIM-3 (T cell immunoglobulin and mucin domain containing-3) antibodies, anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) antibodies or anti-LAG-3 (lymphocyte activation gene 3) antibodies, and even more particularly anti-PD-1 antibodies, anti-PD-L1 (PD-1 ligand) antibodies, anti-CTLA-4 (cytotoxic T lymphocyte associated protein 4) antibodies, anti-NKG2A antibodies, anti-TIM-3 (T cell immunoglobulin and mucin domain containing-3) antibodies or anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) antibodies. More particularly, the at least one immune checkpoint inhibitor according to the present invention may be an anti-PD-1 monoclonal antibody, an anti-PD-L1 monoclonal antibody, an anti-CTLA-4 monoclonal antibody, an anti-NKG2A monoclonal antibody, an anti-TIM-3 monoclonal antibody, an anti-TIGIT monoclonal antibody and an anti-LAG-3 monoclonal antibody, in particular a monoclonal antibody selected from the group consisting of an anti-PD-1 monoclonal antibody, an anti-PD-L1 monoclonal antibody, an anti-CTLA-4 monoclonal antibody, an anti-NKG2A monoclonal antibody, an anti-TIM-3 monoclonal antibody and an anti-TIGIT monoclonal antibody.

[0193] The anti-PD-1 monoclonal antibody may, for example, be selected from the group consisting of Nivolumab, Pembrolizumab, and Cemiplimab.

[0194] The anti-PD-L1 monoclonal antibody may, for example, be selected from the group consisting of Atezolizumab, Avelumab, and Durvalumab.

[0195] The anti-CTLA-4 monoclonal antibody may, for example, be selected from the group consisting of ipilimumab, tremelimumab, and quavonlimab.

[0196] An example of an anti-NKG2A monoclonal antibody is monalizumab.

[0197] The anti-TIM-3 monoclonal antibody may, for example, be selected from the group consisting of Sym023 and sabatolimab.

[0198] The anti-TIGIT monoclonal antibody can be, for example, tiragolumab.

[0199] The anti-LAG-3 monoclonal antibody can be, for example, relatlimab.

[0200] In particular, the ICI may be an anti-PD-L1 monoclonal antibody or an anti-PD-1 monoclonal antibody, in particular an anti-PD-1 monoclonal antibody.

[0201] The vaccine composition, lentiviral vector, lentiviral vector particle or cell and the immune checkpoint inhibitor for use according to the present invention may be administered simultaneously or separately.

[0202] Considering the unexpected synergistic advantageous properties obtained when combining a lentiviral vector according to the invention with an immune checkpoint inhibitor, as demonstrated in the examples, it may be expected that vaccination with a lentiviral vector according to the invention may increase the number of patients eligible for immune checkpoint inhibitor therapy, in particular anti-PD-1 therapy.

[0203] By "concurrently" it is understood that (i) the vaccine composition, lentiviral vector, lentiviral vector particle or cell, and (ii) the immune checkpoint inhibitor can be administered at the same moment, or up to the same day or days, in which case they can be administered in the same composition or they can be administered in separate compositions.

[0204] By "separately", it is understood that (i) the vaccine composition, lentiviral vector, lentiviral vector particle or cell according to the present invention, and (ii) the immune checkpoint inhibitor may be administered at least several days apart, for example at least 2 days apart.

[0205] In particular, when (i) the vaccine composition, lentiviral vector, lentiviral vector particle or cell, and (ii) the immune checkpoint inhibitor are administered separately, the vaccine composition, lentiviral vector, lentiviral vector particle or cell according to the present invention may be administered before the immune checkpoint inhibitor.

[0206] Advantageously, the vaccine composition, lentiviral vector, lentiviral vector particle or cell according to the invention can be administered at least 2 days, in particular at least 4 days, before the administration of the immune checkpoint inhibitor. Thus, the immune checkpoint inhibitor can be advantageously administered at least 2 days, in particular at least 4 days, after the administration of the vaccine composition, lentiviral vector, lentiviral vector particle or cell according to the invention. More particularly, the immune checkpoint inhibitor can be administered 4 days to 1 month, in particular 4 days to 15 days, more particularly 4 days to 10 days after the vaccine composition, lentiviral vector, lentiviral vector particle or cell according to the invention.

[0207] The vaccine composition, lentiviral vector, lentiviral vector particle or cell and the immune checkpoint inhibitor for use according to the present invention may be administered by the same route or by different routes.

[0208] The at least one immune checkpoint inhibitor herein is administered in a therapeutically effective dose, i.e., a dose that produces the effect for which it is administered. The exact dose of the immune checkpoint inhibitor will depend on the purpose of the treatment and will be ascertained by the skilled artisan using known techniques.

[0209] The present invention further relates to a method for the treatment and / or prevention of HPV-induced cancer in an individual in need thereof, comprising administering to said individual at least one lentiviral vector of the invention, a lentiviral vector particle of the invention or an isolated cell of the invention, in particular in the form of a vaccine composition according to the invention.

[0210] The present invention further relates to the use of at least one lentiviral vector of the invention, the lentiviral vector particle of the invention or the isolated cell of the invention for the treatment and / or prevention of HPV-induced cancer in an individual in need thereof, in particular the use of at least one lentiviral vector of the invention, the lentiviral vector particle of the invention or the isolated cell of the invention in the form of a vaccine composition according to the invention.

[0211] The following examples and figures are presented for illustrative purposes and are not intended to be implicit limitations of the present invention.

[0212] Working Example

[0213] Materials and Methods

[0214] mouse

[0215] C57BL6jRj mice were purchased from Janvier Labs (Le Genest-Saint-Isle, France). All animals were maintained under specific pathogen-free conditions and all procedures were performed according to approved animal protocols and in accordance with the recommendations for the proper use and care of laboratory animals. All animal experiments were performed in accordance with the guidelines laid down by French and European regulations for the care and use of laboratory animals.

[0216] Peptides, antibodies, and reagents

[0217] To test the reactivity of the vaccine according to the invention, 15mer overlapping peptides with a purity of 80% or more were ordered from GenScript Biotech (Netherlands). CD4-VioBlue (clone REA604), anti-CD45-VioGreen (clone REA737), anti-FoxP3-Vio515 (clone REA788), anti-CD279 (PD1)-PE (clone REA802), anti-CD8a-PE-Vio770 (clone REA601), anti-CD25-APC (clone REA568), anti-CD11c-FITC (clone REA754), and anti-CD11b-APC-Vio770 (clone REA592) were purchased from Miltenyi Biotec. Anti-mouse H-2kb (clone AF6-88.5), anti-CD274 (PD-L1)-APC (clone MIH5), and anti-CD16 / CD32 (clone 2.4G2) were purchased from BD Biosciences.

[0218] Antibodies were mixed with PBS containing 1% FCS (Gibco).

[0219] Cyclophosphamide was purchased from Sigma, resuspended in PBS (Gibco) and stored at -20°C prior to use.

[0220] cell

[0221] HPV-16 E6 and E7 expressing TC-1 tumor cells were generated as previously described (Lin et al. Cancer Res. 1996 Jan 1;56(1):21-6): Primary lung cells from C57BL6 mice were transformed with HPV-16 E6 and E7 genes and pVEJB expressing an activated human c-Ha-ras oncogene. The TC-1 cell line was cultured in Glutamax RPMI medium (Gibco, supplemented with 100 U / ml penicillin, 100 μg / ml streptomycin and 10% fetal bovine serum).

[0222] Lentiviral vector construction

[0223] The antigen (Ag) construct was cloned into the pFlap-B2m-Ag-WPRE Mutee backbone (see, for example, WO 2016 / 012623). The antigen plasmid contains the essential cPPT / CTS sequence (SEQ ID NO: 37 of the nucleic acid sequence) for transduction of non-mitotic cells. The U3 promoter sequence was deleted from the 3' long terminal repeat (LTR) to avoid vector replication. The beta-2 microglobulin (β2m) promoter controls vaccine antigen expression in all transduced cells, whereby the antigen is preferentially expressed in APCs (Antigen Presenting Cells). In addition, it does not contain any known enhancer sequences that may induce mutagenesis and / or genotoxic effects. The antigen plasmid contains a mutated version of the Woodchuck Hepatitis B Virus (WHV) posttranscriptional regulatory element (WPRE) (SEQ ID NO: 38 of the nucleic acid sequence). The wild-type WPRE region contains a truncated form of the WHV X protein that may have oncogenic properties (Kingsman et al., Gene Ther. 2005 Jan;12(1):3-4). The mutant form of WPRE used in our construct contains a point mutation within the start codon of the X protein, thereby preventing expression of the truncated X protein. Such mutant WPRE sequences do not appear to have oncogenic properties (Themis et al., Mol Ther. 2005 Oct;12(4):763-71).

[0224] The packaging plasmid (pNDK) contains the gag-pol sequence of HIV-1 subtype NDK (GenBank accession number: A34828). The proteins nef, vif, vpr and env are not expressed. Moreover, the substitution of aspartic acid (D) to valine (V) at position 64 (D64V) in the HIV-1 integrase protein sequence (pol gene) is sufficient to block integration without interfering with transgene expression in vitro. The lentiviral particles according to the invention are non-integrating particles.

[0225] Envelope plasmids: pCMV-VSV-G INDco (Indiana) and pCMV-VSV-G NJco (New Jersey) vectors were constructed by subcloning the vesicular stomatitis virus (VSV) G protein (VSV-G) Indiana (GenBank accession number J02428) and New Jersey (GenBank accession number P04882) serotype inserts into the pVAX1 expression vector (Invitrogen). Mammalian codon-optimized synthetic genes (GeneArt) encoding glycoproteins from the following Vesiculoviruses were cloned into the pVAX1 plasmid (Invitrogen): Vesicular Stomatitis Virus Indiana serotype (GenBank: FW591952), New Jersey serotype (GenBank: FW591956), and Cocal virus (GenBank: AF045556.1).

[0226] Generation of lentiviral vector particles

[0227] Non-integrating lentiviral particles were produced by transient calcium phosphate co-transfection of HEK 293 T cells (ATCC) with three plasmids (viral antigen plasmid, envelope expression plasmid and packaging plasmid) according to methods well known in the art after amplifying HEK 293 T cells (ATCC) in DMEM supplemented with 1% penicillin / streptomycin and 10% FCS. The culture medium was replaced by serum-free medium after 24 hours. The supernatant was collected 48 hours after transfection and clarified by centrifugation at 2500 rpm. The viral particles were concentrated by ultracentrifugation (22000 rpm / 88250 g, 1 hour at 4° C.) and resuspended in storage buffer (20 mM Pipes, 75 mM NaCl and 2.5% sucrose).

[0228] Vector titration

[0229] Lentiviral vector titers were determined by quantitative PCR after transduction of cells (HEK 293 T). Aphidicolin was added to HEK293T cells 24 h before transduction and maintained during the entire titering process. Cells were incubated for 30 min in lysis buffer (200 mM Tris, 1% NP40 and 1% Tween 20) containing 50 μg / ml RNase A (sigma). Proteinase K (0.2 mg / ml) was added to the suspension and incubated at 56°C for 4 h. For quantitative PCR, a pair of primers specific for RRE (an element of the Ag vector) and GAPDH (in the host cell) was used. Titers were expressed as transduction units (TU) / mL of vector.

[0230] HPV vaccine design

[0231] The non-oncogenic, immunogenic E6 and E7 protein sequences implemented were selected and modified as previously described herein.

[0232] In particular, four different vaccines have been designed that contain the following lentiviral vectors: The lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) on October 21, 2021 under the accession number I-5759; The lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) on October 21, 2021 under the accession number I-5760; A lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) under accession number I-5761 on October 21, 2021; or Lentiviral vector deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) on October 21, 2021 under accession number I-5762.

[0233] These lentiviral vector particles contain these functional lentiviral vectors, which were quantified by vector titration and expressed as transducing units (TU), as performed in the examples below.

[0234] In vivo immunogenicity of lentiviral vector vaccines (LV vaccines)

[0235] Naive C57BL6 female mice were vaccinated with an LV vaccine according to the invention (i.e., lentiviral vector particles of the invention containing a functional lentiviral vector of the invention) by intramuscular (im) injection in 50 μL of diluent. After 14 days, splenocytes were prepared and restimulated overnight for IFNg ELISPOT with four different HPV peptide pools (each peptide at 2 μg / mL final). Each peptide pool corresponds to one of the following non-oncogenic antigen variants: a non-oncogenic variant of the E6 protein of HPV16, a non-oncogenic variant of the E7 protein of HPV16, a non-oncogenic variant of the E6 protein of HPV17, and a non-oncogenic variant of the E7 protein of HPV17. They are composed of overlapping 15-mers (with 11 a.a. overlap) corresponding to the full selected antigens.

[0236] In vivo tumor vaccination treatment

[0237] For in vivo tumor experiments, 1.10 6 TC-1 cells were injected subcutaneously (sc) into the right flank of 7-9 week old C57BL / 6 mice (mice were shaved with an electric shaver prior to injection). When the mean tumor volume reached the expected range, mice were randomized and injected with the LV vaccine of the present invention by intramuscular (im) injection. Mice were monitored for tumor growth three times a week by measuring tumor diameter with a vernier caliper. For ethical reasons, tumors were not allowed to grow beyond 1500 mm 3 Superficially, mice had to be euthanized.

[0238] Immunogenicity of the LV vaccine of the present invention in human PBMCs

[0239] Frozen human PBMCs (StemCell) were gently thawed and stained with 0.5 μM CFSE (Thermofischer) for 10 min at 37° C. Cells were then plated in complete RPMI (10% FCS, 10 mM Hepes (Gibco), 100 U / ml penicillin, 100 μg / ml streptomycin, 0.1 mM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco)) at 0.2×10 per well in round-bottom 96-well plates. 6 After 7 days, cells are centrifuged and fresh complete RPMI (pre-warmed) is added. After another 7 days (total 14 days), cells are stained with fluorescent antibodies and data acquired by flow cytometry (MACSQuant analyzer).

[0240] Cellular analysis of tumor immune infiltrates

[0241] Tumors were treated with a Mouse Tumor Dissociation kit (Miltenyi). The cell suspension was filtered through a 70 μm pore filter and treated with red blood cell lysis buffer (Sigma), then washed and centrifuged at 1200 rpm for 5 min. The harvested cells were stained as described below.

[0242] Near IR LD (Invitrogen), FcγII / III receptor blocking anti-CD16 / CD32 (clone 2.4G2, BD Biosciences), APC-anti-CD11b (clone N418, BD Biosciences), and BV421-anti-NKp46 (clone 29A1.4, Biolegend) were used to detect NK.

[0243] Samples were acquired on an Attune NxT cytometer (Invitrogen) and data were analyzed with FlowJo software (Treestar, OR, USA).

[0244] Intracellular cytokine staining

[0245] Spleen cells from immunized mice were obtained by tissue homogenization and passage through a 100 μm nylon filter (Cell Strainer, BD Biosciences) and plated at 4 × 10 6Cells were seeded at 1000 x 1000 cells / well. Spleen cells were stimulated for 6 h in the presence of 10 μg / mL of homologous or control peptide, 1 μg / mL of anti-CD28 (clone 37.51) and 1 μg / mL of anti-CD49d (clone 9C10-MFR4.B) mAbs (BD Biosciences). For the last 3 h of incubation, cells were treated with a mixture of Golgi Plug and Golgi Stop (both BD Biosciences). PE-Cy7-anti-CD107a (clone 1D4B, BioLegend) mAb was also added to the cultures at this time point. Cells were then harvested, washed with PBS containing 3% FBS and 0.1% NaN3 (FACS buffer) and incubated with a mixture of Near IR Live / Dead (Invitrogen), FcγII / III receptor blocking anti-CD16 / CD32 (clone 2.4G2), PerCP-Cy5.5-anti-CD3ε (clone 145-2C11), PE-Cy7-anti-CD4 (clone RM4-5) and BV711-anti-CD8 (clone 53-6.7) mAbs (BD Biosciences or eBioscience) for 25 min at 4° C. Cells were washed twice in FACS buffer and then permeabilized using the Cytofix / Cytoperm kit (BD Bioscience). Cells were then washed twice with PermWash 1X buffer from the Cytofix / Cytoperm kit and incubated with a mixture of BV421-anti-IL-2 (clone JES6-5H4), FITC-anti-TNF (MP6-XT22), APC-anti-IFN-γ (clone XMG1.2) and BV605-anti-IL-17A (clone TC11-18H10) mAbs (BD Biosciences) or appropriate control Ig isotypes for 30 min at 4°C. Cells were then washed twice in PermWash and once in FACS buffer, and then fixed overnight at 4°C with Cytofix (BD Biosciences). Cells were acquired on an Attune NxT cytometer system (Invitrogen) and data analysis was performed using FlowJo software (Treestar, OR, USA).

[0246] Example 1: HPV vaccine of the present invention is immunogenic in vivo

[0247] To determine the ability of the vaccines of the present invention to elicit an immune response, recipient mice were immunized with the four vaccines (five mice per tested vaccine and control group).

[0248] Mice were incubated with 1 x 10 6 lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5759, the lentiviral vector deposited at the CNCM under accession number I-5760, the lentiviral vector deposited at the CNCM under accession number I-5761, or the lentiviral vector deposited at the CNCM under accession number I-5762. 7 TU or 50 μL of diluent were injected intramuscularly (im). 14 days later, splenocytes were prepared and restimulated overnight with four different peptide pools (each peptide at 2 μg / mL final) for IFNg ELISPOT. The results obtained are shown in Figure 1.

[0249] Example 2: The HPV vaccine, which is one of the vaccines of the present invention, completely eliminates transplanted tumors in vivo.

[0250] TC-1 tumor cells have been widely used as a preclinical model to study HPV-induced tumors (Kim, JW et al. Gene therapy vol. 11, 12 (2004): 1011-8). These lung tumor cells were modified to express E6 and E7 from HPV16 (Lin et al. Cancer Res. 1996 Jan 1; 56(1): 21-6).

[0251] After TC-1 cells were injected subcutaneously (sc) into the mice, solid tumors were rapidly found at the injection site, and tumors in untreated animals grew and reached an ethical end point in 30-40 days. To test the efficacy of the lentiviral vector particles of the present invention, TC-1 cells were injected subcutaneously (sc) and tumor volumes were measured (caliper measurements) every other day. The average tumor volume was 70 mm 3 At 1 h after immunization, mice were randomized and administered 1 x 10 6 doses of LV-GFP Indiana (as a control), Indiana lentiviral vector particles containing I-5759, Indiana lentiviral vector particles containing I-5760, Indiana lentiviral vector particles containing I-5761, or Indiana lentiviral vector particles containing I-5762. 8 Vaccinations were administered with TU via intramuscular (im) injection.

[0252] The results obtained are shown in FIG.

[0253] Rapid and highly efficient elimination of tumors is observed in 100% of animals vaccinated with lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5762 and lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5759, in 87.5% of animals vaccinated with lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5760, and in 75% of animals vaccinated with lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5761.

[0254] A vaccine comprising lentiviral vector particles containing a lentiviral vector deposited at the CNCM under accession number I-5759 and a vaccine comprising lentiviral vector particles containing a lentiviral vector deposited at the CNCM under accession number I-5762 show comparable tumor elimination rates (higher than I-5760 and I-5761), but I-5759 vaccination results in complete tumor elimination in an average of 37.5 days (± 7.4 SD) whereas I-5762 vaccination results in complete tumor elimination 54.7 days after vaccination.

[0255] The inventors were surprised to observe that the most immunogenic vectors were not the most prophylactically effective, and that the ranking of immunogenicity did not apply to antitumor efficacy. Indeed, lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759 were the most efficient antitumor vaccines, whereas lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5760 and lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5762 were the more immunogenic vectors when measuring IFN-γ production.

[0256] Example 3: A single administration of the HPV vaccine of the present invention is effective against tumor recurrence.

[0257] Relapse is common in most cancer types and is defined as the return of disease after a period of improvement, often due to a small number of tumor cells surviving the initial treatment forming new tumors weeks, months, or years after treatment.

[0258] A. To mimic recurrence in our model, mice that had cleared the primary tumor were re-challenged on the other flank on day 60. Control mice (untreated) were also injected subcutaneously (sc) to confirm tumor cell injection.

[0259] The results obtained are shown in FIG.

[0260] This figure shows that subcutaneous (sc) injection of TC-1 cells in control mice results in the formation of solid tumors that reach the ethical limit in size in less than 30 days. Tumor growth in rechallenged mice (mice whose right flank tumors disappeared after vaccination) was strongly suppressed. Tumor growth was observed during the first 6 days, and tumor elimination began thereafter.

[0261] The tumors completely disappeared within 13–16 days after implantation. A single vaccination of tumor-bearing mice resulted in complete disappearance of the primary tumor, and these mice rapidly cleared secondary tumors, providing strong protection against recurrence.

[0262] B. 119 days after the first implantation, the primary tumor in the other flank disappeared in the mouse. 6 Additional experiments were performed in which mice were re-challenged with TC-1 tumor cells and maintained without any treatment. Control mice (untreated) were also injected subcutaneously (sc) to confirm tumor cell injection.

[0263] The results obtained are shown in FIG.

[0264] All of the rechallenged mice were still alive 145 days after the initial tumor challenge, demonstrating that a single injection of the vaccine according to the present invention effectively promoted a strong anti-tumor memory protective immune response, thereby efficiently generating a T cell response against a new challenge.

[0265] Example 4: The therapeutic effect of the anti-HPV vaccine of the present invention is dose-dependent.

[0266] To determine the effect of lower doses of the vaccine, an efficacy study was performed on mice bearing TC1 tumors. Mice were administered 1x10 doses of a vaccine according to the invention comprising lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759.8 or 1x10 7 TU / mouse was vaccinated.

[0267] In particular, 1x10 6 TC-1 cells were injected into the flank of the animals and tumor volumes were measured (caliper measurement) twice weekly. The average tumor volume was 80 mm 3 At 4 °C, mice were randomized to receive either diluent (control), 1x10 7 TU or 1x10 8 Vaccination was administered with TU's I-5759 vaccine via intramuscular (im) injection.

[0268] The results obtained are shown in FIG.

[0269] 1x10 8 Vaccination with TU allowed complete and rapid disappearance of the tumor (<20 days after vaccination), whereas 1x10 7 We observed that the TU vaccination dose had a partial effect on tumor growth: 3 / 6 (50%) mice had tumor-free tumors 22 days after vaccination, while the other mice showed a first reduction 15-18 days (5-10 days) after vaccination, but tumor growth could not be controlled thereafter.

[0270] A single low dose (1x10 7 ) showed partial inhibition comparable to that observed with three injections of an adenoviral vector-based vaccine (Rice, AE et al. Cancer gene therapy vol. 22, 9 (2015): 454-62). This suggests that the optimal dose of the vaccine according to the present invention is more efficient than the adenoviral platform. Moreover, efficacy at low doses is most likely enhanced by a second injection of the vaccine.

[0271] Example 5: Vaccination according to the present invention inhibits CD4 + and CD8 +Increases T cell infiltration and decreases Tregs in treated tumors.

[0272] To further understand the antitumor mechanisms induced after vaccination with lentiviral vectors according to the invention, tumor infiltration was investigated. 6 TC1 tumor cells were injected subcutaneously (sc) into the flank of the animals and tumor volumes were measured (caliper measurement) twice weekly. The mean tumor volume was 80 mm 3 At 4 °C, mice were randomized to receive either diluent (control) or 1x10 7 TU or I-5759 1x10 8 Patients were vaccinated with either TU via intramuscular (im) injection.

[0273] Ten days after vaccination, tumors were harvested, digested and analyzed by flow cytometry. FACS staining was performed and data was acquired on a Macsquant facs according to methods well known in the art.

[0274] The results obtained are shown in FIG.

[0275] Tumors from vaccinated mice contained more CD8 + T cells and CD4 + T cells were infiltrating the tumor. + T cells and CD4 + The ratio of CD25 in the tumor to CD45 in the tumor was increased by approximately 4-fold and 3-fold, respectively. + FoxP3 + CD4 + The proportion of regulatory T cells (Treg) was strongly reduced in treated animals.

[0276] These observations suggest that a vaccine containing the lentiviral vector of the present invention can target CD8 + T cells and CD4 + This is of great importance as it suggests not only improving T cell recruitment but also reducing the proportion of Tregs within the tumor.

[0277] Example 6: The HPV vaccine of the present invention completely eliminates large tumors in vivo.

[0278] Well-established tumors are known to be more difficult to eliminate than small and early tumors. Most vaccines tested in the TC1 model have weak efficacy when administered at later time points (Rice, AE et al. Cancer gene therapy vol. 22, 9 (2015): 454-62; Berraondo, Pedro et al. Cancer research vol. 67, 18 (2007): 8847-55). 1x10 6 TC1 tumors were injected subcutaneously (sc) into the flank of the animals. The average tumor volume was approximately 300 mm. 3 At 1 h, mice were randomized to receive either diluent (control) or 1 x 10 of a vaccine according to the invention comprising lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759. 8 Mice were vaccinated with TU by intramuscular (im) injection. Tumor volumes were measured twice weekly with calipers.

[0279] The results obtained are shown in FIG.

[0280] Vaccines according to the invention prove highly effective in completely eliminating established HPV-induced tumors.

[0281] Example 7: The HPV vaccine of the present invention induces activation of human PBMC in vitro.

[0282] To confirm that the vaccine according to the invention can induce T cell responses in human cells, human PBMCs (stem cells) were labeled with CFSE and cultured in the absence (unstimulated) or presence of the vaccine according to the invention (I-5759). After 2 weeks of culture, cell proliferation and activation were measured.

[0283] CD8 + T cells and CD4 + T cell proliferation (measured by CFSE dilution) and expression of the CD25 activation marker were increased by adding the lentiviral vector of the invention during culture.

[0284] The results obtained are shown in FIG.

[0285] Thereby it can be concluded that antigen presenting cells derived from PBMC are transduced by the HPV vaccine according to the invention and are able to process antigens and activate T cells.

[0286] Example 8: Systemic T cell immunity and effector T cell phenotype induced by the HPV vaccine of the present invention

[0287] To gain further insight into the quality of the T cell response induced, mice injected with control Lenti (LV-empty Indiana) or with a vaccine according to the invention comprising lentiviral vector particles containing the lentiviral vector deposited at the CNCM under accession number I-5759 were either left untreated or injected with the immunodominant H-2D b E7 of ETTDPDRAHYNIVTF and PDRAHYNIVTFCCKC containing the restricted RAHYNIVTF epitope HPV16 The cells were stimulated in vitro with a mixture of derived peptides (Feltkamp MC et al., Eur J Immunol 1993;23:2242-9) and analyzed by intracellular staining (ICS) for IL-2, TNF-α and IFN-γ.

[0288] The results obtained are shown in FIG. 9A.

[0289] Stimulation with these peptides increased the CD8 + T cell responses were detected. Functional CD8 + T cell effectors are IFN-γ + (single positive), TNF-α + IFN-γ + or IL-2 + IFN-γ + (double positive) and IL-2 + TNF-α + IFN-γ + (triple positive) subset (see Fig. 9B).

[0290] IFN-γ + CD8 + The majority of T cells also expressed the surface CD107a degranulation marker, indicating the effector properties of these T cells (see FIG. 9B).

[0291] Example 9: Characteristics of tumor cells and tumor-infiltrating innate immune cells in mice vaccinated with the HPV vaccine of the present invention

[0292] Cytometric characterization of intra-tumoral infiltrates 11 days after vaccination, thus during the tumor regression phase, showed a significant increase in the proportion of natural killer (NK) cells in regressing tumors of mice vaccinated with a vaccine according to the present invention comprising lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759.

[0293] The results are shown in FIG.

[0294] Example 10: Suboptimal Lenti-HPV-07 vaccination acts synergistically with anti-PD1 immunotherapy.

[0295] The inventors further investigated the possible synergistic effect of suboptimal Lenti-HPV-07 (I-5759) vaccination and anti-PD-1 therapy.

[0296] Anti-PD-1 treatment was started 4 days (D17, i.e. 17 days after subcutaneous (sc) administration of TC-1 cells to mice) after injection of a vaccine according to the invention comprising lentiviral vector particles comprising the lentiviral vector deposited at the CNCM under accession number I-5759 (D13, i.e. 13 days after subcutaneous (sc) administration of TC-1 cells to mice). Several injections of anti-PD-1 were performed (D17 as described above, then D20, D22, D24, D28, D31).

[0297] In particular, the experiment was carried out on three identical groups of mice implanted with tumors. In the first group (10 mice - control group), mice were administered LV-empty Indiana (D13) (as a control) and then 4 days later anti-PD-1 monoclonal antibody (D17, then D20, D22, D24, D28 and D31). In the second group (12 mice - control group), mice were administered the vaccine according to the invention (I-5759) (D13) and then 4 days later control antibody (isotype control) (D17, then D20, D22, D24, D28 and D31). In a third group (14 mice), mice were administered a vaccine according to the invention (D13) (I-5759) followed 4 days later by mAb anti-PD-1 (D17, then D20, D22, D24, D28 and D31).

[0298] The results are shown in Figures 12A and 12B.

[0299] Suboptimal doses of the vaccine, which elicited insufficient antitumor T cell responses, acted synergistically with anti-PD-1 to increase tumor regression rates.

[0300] Six of 14 mice achieved complete tumor regression, and the other two showed partial tumor regression. In the latter, the tumor volume was reduced by 67% and then the tumor recurred 6-7 days after the end of anti-PD-1 treatment, highlighting the need for repeated injections of anti-PD-1 until the tumor completely disappeared. Of the 12 mice treated with the vaccine of the present invention alone, only three showed partial tumor regression. Thus, the survival rate of mice was significantly increased in the combo treatment group compared to mice treated with a suboptimal dose of Lenti-HPV-07 (Figure 12B). Therefore, a synergistic anti-tumor effect can be obtained when the Lenti-HPV-07 vaccine candidate is combined with anti-PD1 checkpoint inhibition treatment.

[0301] Example 11: A single injection of a vaccine according to the invention cures mice with pulmonary metastatic lesions induced by intravenous injection of TC1-nLuc cells

[0302] The TC1 parental cell line was stably transduced with an integrative lentiviral vector encoding a nanoluciferase reporter and puromycin N-acetyltransferase (for selection) under the ubiquitin (UBC) promoter. After selection with puromycin, the cells were subcloned to obtain the TC1-nLuc cell line.

[0303] Six-week-old C57BL / 6JRj mice purchased from Janvier Laboratory were intravenously injected with 150,000 TC1-nLuc cells. 9 TU / mouse of Lenti-HPV-07 or control Lenti (empty vector) were injected intramuscularly.

[0304] Bioluminescence imaging of live animals was performed using an IVIS Imaging System (IVIS Spectrum, Perkin Elmer) connected to a charge-coupled device camera. Prior to bioluminescence imaging, mice were anesthetized with 2% isoflurane in oxygen and maintained in a control flow of 1.5% isoflurane in oxygen through a nose cone during imaging. The substrate furimazine (Z108) (provided by Dr. Yves Janin, Institut Pasteur) was dissolved at 2 mg / ml in acidified ethanol. Z108 was further diluted in sterile D-PBS to the desired concentration (0.4 mg / kg) before intravenous injection. Mice were then immediately placed in the imaging chamber and imaged. Sequential images were taken under autoexposure settings with a maximum exposure time of 2 min.

[0305] Images from each experimental set were analyzed using Living Image Software (Ver.2.50.1 Xenogen). Measurements from regions of interest were taken, and luminescence values ​​were evaluated as total flux (photons / sec). The abdomen and torso of the mice were shaved to increase the signal-to-noise ratio. Baseline signals were obtained from naive mice injected with Z108, i.e., mice not injected with TC1-nLuc cells or lentiviral vectors.

[0306] The results obtained are shown in Figures 13A and 13B.

[0307] The inventors have confirmed that a single intramuscular injection of the Lenti-HPV-07 vaccine (I-5759) according to the present invention completely eradicates subcutaneously engrafted TC1 tumors in 100% of animals. However, in humans, many cancers, including those mentioned above, including HPV-induced cancers, occur at mucosal sites.

[0308] Therefore, the present study evaluated the tumor growth inhibitory potential of Lenti-HPV-07 at mucosal sites.

[0309] To address this question, a TC1 cell line (TC1-nLuc) stably expressing a nanoluciferase reporter gene was developed. After intravenous injection of TC1-nLuc, mice readily developed lung metastases.

[0310] Longitudinal tumor progression was followed in live animals by bioluminescence imaging.

[0311] Five days after tumor injection, mice were infected with Lenti-HPV-07(1.10 9 TU / mouse) or control Lenti (empty vector) was injected intramuscularly once (Figure 13A).

[0312] All mice treated with Lenti-HPV-07 were cured 22 days after tumor injection, whereas lung metastases continued to grow in the control group. The observed difference between the mean bioluminescence signals in the two groups was nearly statistically significant (Figures 13A and 13B).

[0313] This observation clearly demonstrates that the vaccine according to the invention is able to eradicate lung tumors as efficiently as tumors formed subcutaneously.

[0314] array

[0315] SEQ ID NO:1 is the nucleic acid sequence encoding the E6 protein from HPV 16 (NC_001526.4). ATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCATAGTATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAA TTAGTGAGTATAGACATTATTGTTATAGTTTGTATGGAACAACATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTGGACCGGTCGATGTATGTCTTGTTGGAATCATCAAGAACACGTAGAGAAACCCAGCTGTAA

[0316] SEQ ID NO:2 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. GACCCCCAAGAACGGCCCAGAAAGCTGCCCCAGCTGTGCACCGAGCTGCAGACCACCATCCACGACATCATCCTGGAATGCGTGTACTGCAAGCAGCAGCTGCTGAGAAGAGAGGTGTACGACTTCGCCTTCCGGGACCTGTGCATCGTGTACCGGAACCCCTACGCCGTGTGCGACAAGTGCC TGAAGTTCTACAGCAAGATCAGCGAGTACCGGCACTACTGCTACAGCCTGTACGGCACCACCCTGGAACAGCAGTACAACAAGCCCCTGTGCGACCTGCTGATCAGATGCATCAACTGCCAGAAGCCCCTGCGGTTCCACAACATCCGGGGCAGATGGACCGGCCGGTGCATGAGCTGCTGCAGA

[0317] SEQ ID NO:3 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. ATGGGCACCCTGGGCATCGGTGTGCCCCATCGACCCCCAAGAACGGCCCAGAAAGCTGCCCCAGCTGTGCACCGAGCTGCAGACCACCATCCACGACATCATCCTGGAATGCGTGTACTGCAAGCAGCAGCTGCTGAGAAGAGAGGTGTACGACTTCGCCTTCCGGGACCTGTGCATCGTGTACCGGAACCCCTACGCCG TGTGCGACAAGTGCCTGAAGTTCTACAGCAAGATCAGCGAGTACCGGCACTACTGCTACAGCCTGTACGGCACCACCCTGGAACAGCAGTACAACAAGCCCCTGTGCGACCTGCTGATCAGATGCATCAACTGCCAGAAGCCCCTGCGGTTCCACAACATCCGGGGCAGATGGACCGGCCGGTGCATGAGCTGCTGCAGA

[0318] SEQ ID NO:4 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. ATGGACCCCCAAGAACGGCCCAGAAAGCTGCCCCAGCTGTGCACCGAGCTGCAGACCACCATCCACGACATCATCCTGGAATGCGTGTACTGCAAGCAGCAGCTGCTGAGAAGAGAGGTGTACGACTTCGCCTTCCGGGACCTGTGCATCGTGTACCGGAACCCCTACGCCGTGTGCGACAAGTGC CTGAAGTTCTACAGCAAGATCAGCGAGTACCGGCACTACTGCTACAGCCTGTACGGCACCACCCTGGAACAGCAGTACAACAAGCCCCTGTGCGACCTGCTGATCAGATGCATCAACTGCCAGAAGCCCCTGCGGTTCCACAACATCCGGGGCAGATGGACCGGCCGGTGCATGAGCTGCTGCAGA

[0319] SEQ ID NO:5 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. TTTCAGGACCCCCAGGAAAGGCCCAGGAAGTTGCCCCAGCTCTGCACCGAACTGCAGACCACCATTCATGACATCATCCTCGAATGCGTGTACTGCAAGCAGCAGCTCCTGAGGAGGGAGGTGTACGATTTCGCCTTCAGAGACGGCTGTATCGTCTACAGGAACCCCTATGCCGTCTGCGACAAAT GCCTGAAGTTTTATTCCAAGATCTCCGAGTACAGGCACTATTGCTACAGCCTGTATGGGACCACCCTGGAGCAGCAGTACAACAAGCCCCTGTGCGACCTCCTGATCAGGTGCATCAACTGCCAGAAGCCCCTGAGGTTCCACAACATCCGCGGCAGGTGGACCGGAAGGTGCATGTCCTGCTGCAGG

[0320] SEQ ID NO:6 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 16. TTCCAGGACCCCCAGGAGAGGCCCAGGAAACTGCCCCAGTTGTGCACCGAGCTCCAGACAACCATCCACGACATCATCCTGGAGTGCGTGTACTGTAAGCAGCAGTTGCTGAGGAGAGAGGTGTATGACTTCGCCTTCAGAGACGGATGCATTGTCTATAGGAACCCCTACGCCGTGTGCGACAAGTGC CTGAAGTTCTACTCCAAGATCAGTGAGTACAGGCATTACTGCTACAGCCTGTATGGAACCACACTGGAACAGCAGTACAACAAGCCCCTGTGCGACCTCCTGATTAGGTGCATCAACTGCCAGAAGCCCCTCAGGTTCCACAACATCCGGGGCAGGTGGACCGGAAGGTGCATGTCCTGCTGCAGGTCC

[0321] SEQ ID NO:7 is the amino acid sequence of the wild-type (WT) E6 protein from HPV 16. MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL

[0322] SEQ ID NO:8 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV16. DPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCR

[0323] SEQ ID NO:9 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV16. MGTLGIVCPIDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCR

[0324] SEQ ID NO:10 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 16. MDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCR

[0325] SEQ ID NO:11 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 16. FQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCR

[0326] SEQ ID NO:12 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV16. FQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRS

[0327] SEQ ID NO:13 is a nucleic acid sequence encoding the E7 protein from HPV 16 (NP-041326.1). ATGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAG CCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACCATAA

[0328] SEQ ID NO:14 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 16. ACCCCCACCCTGCACGAGTACATGCTGGACCTGCAGCCCGAGACAACCGACCCCGACCGGGCCCACTACAATATCGTGACCTTCTGCTGCAAGTGCGACAGCACCCTGCGGCTGTGCGTGCAGAGCACCCACGTGGACATCCGGACCCTGGAAGATCTGCTGATGGGCACCCTGGGCATCGTGTGCCCCATT

[0329] SEQ ID NO:15 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 16. CCCGGAGACACCCCCACCCTGCACGAATACATGCTGGACCTGCAGCCCGAAACCACCGACCCCGACCGCGCTCACTACAACATCGTTACATTCTGTTGTAAATGCGACTCCACCCTGAGAAGATGCGTGCAGTCCACCCACGTGGACATCAGGACCCTGGAGGACCTCCTCATGGGAACCCTGGGTATCGTCTGCCCCATC

[0330] SEQ ID NO:16 is the amino acid sequence of the wild-type (WT) E7 protein from HPV 16. MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP

[0331] SEQ ID NO:17 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 16. TPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPI

[0332] SEQ ID NO:18 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 16. PGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPI

[0333] SEQ ID NO:19 is the nucleic acid sequence encoding the E6 protein from HPV 18 (MF288727.1). ATGGCGCTTTGAGGATCCAACACGGCGACCCTACAAGCTACCTGATCTGTGCACGGAACTGAACACTTCACTGCAAGACATAGAAATAACCTGTGTATATTGCAAGACAGTATTGGAACTTACAGAGGTATTTGAATTTGCATTTAAAGATTTATTTGTGGTGTATAGAGACAGTATACCGCATGCTGCATGCCATAAATGTATAGATTTTTATTCTAGAATTAGAGAATTAAGAC ATTATTCAGACTCTGTGTATGGAGACACATTGGAGAAACTAACTAACACTGGGTTATACAATTTATTAATAAGGTGCCTGCGGTGCCAGAAACCGTTGAATCCAGCAGAAAAACTTAGACACCTTAATGAAAAACGACGATTCCACAACATAGCTGGGCACTATAGAGGCCAGTGCCATTCGTGCTGCAACCGAGCACGACAGGAAAGACTCCAACGACGCAGAGAAACACAAGTATAA

[0334] SEQ ID NO:20 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. CCCTACAAGCTGCCTGACCTGTGTACAGAGCTGAACACCTCCCTGCAGGACATCGAGATCACCTGTGTGTATTGCAAGACCGTGCTGGAACTGACCGAGGTGTTCGAGTTTGCCTTCAAGGATCTGTTCGTGGTGTACCGGGACAGCA TCCCCCAGCCGCCTGCCACAAGCTGGAAAAGCTGACCAACACCGGCCTGTACAACCTGCTGATTCGGTGCCTGCGGTGTCAGAAGCCTCTGAACCCCGCCGAGAAGCTGCGGCACCTGAACGAGAAGCGGAGATTCCACAATATCGCC

[0335] SEQ ID NO:21 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. CCCTACAAGCTGCCTGACCTGTGTACAGAGCTGAACACCTCCCTGCAGGACATCGAGATCACCTGTGTGTATTGCAAGACCGTGCTGGAACTGACCGAGGTGTTCGAGTTTGCCTTCAAGGATCTGTTCGTGGTGTACCGGGACAGCATCCCCCACGCCGCCTGCCACAAG

[0336] SEQ ID NO:22 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. CCCTACAAGCTGCCCGATCTGTGCACAGAGCTGAACACCTCCCTGCAGGACATCGAGATCACCTGCGTCTACTGCAAGACCGTGCTGGAACTGACCGAGGTGTTCGAATTCGCCTTCAAGGACGGCTTCGTGGTGTACAGGGACAGCA TTCCCCACGCCGCCTGCCATAAGCTGGAGAAACTGACCAACACCGGACTGTATAACCTGCTGATCAGGTGTCTGAGGTGCCAGAAGGCAGAGAAACTGAGACATCTGAACGAGAAAAGGAGGTTCCACAATATTGCCGGGCACTGATAA

[0337] SEQ ID NO:23 is a nucleic acid sequence encoding a non-oncogenic mutant of the E6 protein from HPV 18. ATGAGGCGGCCCTACAAGCTGCCCGACCTGTGCACCGAGCTGAACACCTCCCTGCAGGACATCGAGATCACCTGCGTGTACTGCAAGACCGTGCTGGAGCTGACCGAGGTGTTCGAATTCGCATTCAAGGACGGATTCGTCGTGTATAGG GACAGCATTCCACACGCCGCCTGCCACAAGCTGGAGAAATTGACTAACACCGGACTGTATAATCTGCTGATCCGGTGCCTGAGGTGTCAGAAGGCCGAGAAGCTGAGGCATCTGAACGAGAAAAGGAGATTCCACAATATCGCCGGACAC

[0338] SEQ ID NO:24 is the amino acid sequence of the wild-type (WT) E6 protein from HPV 18. MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV

[0339] SEQ ID NO:25 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. PYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIA

[0340] SEQ ID NO:26 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. PYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYRDSIPHAACHK

[0341] SEQ ID NO:27 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. PYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGH

[0342] SEQ ID NO:28 is the amino acid sequence of a non-oncogenic mutant of the E6 protein from HPV 18. MRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGH

[0343] SEQ ID NO:29 is the nucleic acid sequence encoding the E7 protein from HPV 18 (NC_001357.1). ATGCATGGACCTAAGGCAACATTGCAAGACATTGTATTGCATTTAGAGCCCAAAATGAAATTCCGGTTGACCTTCTATGTCACGAGCAATTAAGCGACTCAGAGGAAGAAAACGATGAAATAGATGGAGTTAATCATCAACATTTACCAGCCCGACGA GCCGAACCACAACGTCACACAATGTTGTGTATGTGTTGTAAGTGTGAAGCCAGAATTGAGCTAGTAGTAGAAAGCTCAGCAGACGACCTTCGAGCATTCCAGCAGCTGTTTCTGAACACCCTGTCCTTTGTGTGTCCGTGGTGTGCATCCCAGCAGTAA

[0344] SEQ ID NO:30 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 18. AAGGCCACACTGCAGGATATCGTGCTGCACCTGGAACCCCAGAACGAGATCCCCGTGGACAGCGAGGAAGAGAACGACGAGATCGACGGCGTGAACCACCAGCATCTGCCCGCCAGAAGGGCCGAGCCCC AGAGACACACCATGCTGTGCATGTGTTGCAAATGCGAGGCCCGGATCAAGCTGGTGGTGGAAAGCAGCGCCGACGACCTGCGGGCCTTCCAGCAGCTGTTCCTGAACACCCTGTCCTTCGTGTGCCCTTGG

[0345] SEQ ID NO:31 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 18. GGACCTAAAGCCACCCTCCAGGACATCGTGCTGCACCTGGAGCCCCAGAACGAGATCCCCGTCGACTCAGAGGAGGAGAACGACGAAATTGACGGCGTCAACCACCAGCACCTGCCCGCTCGCAGAGCCGAAC CCCAGAGACACACCATGCTCTGCATGTGCTGCAAATGCGAGGCCCGGATTAAGCTGGTGGTGGAGAGCTCCGCCGACGATCTGAGAGCCTTCCAGCAGCTCTTCCTGAACACCCTGTCCTTCGTGTGCCCCTGG

[0346] SEQ ID NO:32 is a nucleic acid sequence encoding a non-oncogenic mutant of the E7 protein from HPV 18. GGACCTAAAGCCACCCTCCAGGACATCCGTCTGGAGCCCCAGAACGAGATCCCCGTCGACTCAGAGGAGGAGAACGACGAAATTGACGGCAACCACCAGCACCTGCCCGCTCGCAGAGCCGAACCC CAGAGACACACCATGCTCTGCATGTGCTGCAAATGCGAGGCCCGGATTAAGCTGGTGGTGGAGAGCTCCGCCGACGATCTGAGAGCCTTCCAGCAGCTCTTCCTGGATTCCTTCGTGTGCCCCTGG

[0347] SEQ ID NO:33 is the amino acid sequence of wild-type (WT) E7 protein from HPV 18. MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIELVVESSADDLRAFQQLFLNTLSFVCPWCASQQ

[0348] SEQ ID NO:34 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 18. KATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPW

[0349] SEQ ID NO:35 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 18. GPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPW

[0350] SEQ ID NO:36 is the amino acid sequence of a non-oncogenic mutant of the E7 protein from HPV 18. GPKATLQDIRLEPQNEIPVDSEEENDEIDGNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLDSFVCPW

[0351] SEQ ID NO:37 is a nucleic acid sequence encoding the cPPT / CTS sequence. AATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTT

[0352] SEQ ID NO:38 is a nucleic acid sequence encoding a variant of the Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE). TTCCCGATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCC TTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTT CCCCCTCCCTATTGCCAGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCGCGGCTGCTCGCCTGTGTTGCCACCTGGA TTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0353] SEQ ID NO:39 is RAHYNIVTF H-2D b -Synthetic E7 containing restricted T cell epitopes HPV16 -derived peptide. ETTDPDRAHYNIVTF

[0354] SEQ ID NO:40 is RAHYNIVTF H-2D b -Synthetic E7 containing restricted T cell epitopes HPV16 -derived peptide. PDRAHYNIVTFCCKC

[0355] SEQ ID NO:41 is the nucleic acid sequence encoding the antigen construct of the lentiviral vector deposited at the CNCM under accession number I-5759.

[0356] SEQ ID NO:42 is the amino acid sequence of the antigen construct encoded by the lentiviral vector deposited at the CNCM under accession number I-5759. MPGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIASQAFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCR SAGPGPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWVGEPGR TIPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGH

[0357] SEQ ID NO:43 is the nucleic acid sequence encoding the antigen construct of the lentiviral vector deposited at the CNCM under accession number I-5760.

[0358] SEQ ID NO:44 is the amino acid sequence of the antigen construct encoded by the lentiviral vector deposited at the CNCM under accession number I-5760. MFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRGPDDPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLT NTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGPGDTTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIGPDDKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWA

[0359] SEQ ID NO:45 is the nucleic acid sequence encoding the antigen construct of the lentiviral vector deposited at the CNCM under accession number I-5761.

[0360] SEQ ID NO:46 is the amino acid sequence of the antigen construct encoded by the lentiviral vector deposited at the CNCM under accession number I-5761. MRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNI AGHFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLC DLLIRCINCQKPLRFHNIRGRWTRGRCMSCCRSAGPGPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWAGPGDTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIA

[0361] SEQ ID NO:47 is the nucleic acid sequence encoding the antigen construct of the lentiviral vector deposited at the CNCM under accession number I-5762.

[0362] SEQ ID NO:48 is the amino acid sequence of the antigen construct encoded by the lentiviral vector deposited at the CNCM under accession number I-5762. MGPKATLQDIVLHLEPQNEIPVDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPGEPGRTIPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDGFVVYRDSIPHAACHKLEKLTNTGLYNLLIRCLRCQKAEKLRHLNEKRRFHNIAGPG DTPTLHEYMLDLQPETTDPDRAHYNIVTFCCKCDSTLRRCVQSTHVDIRTLEDLLMGTLGIVCPIASQAFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDGCIVYRNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLRFHNIRGRWTGRCMSCCRS

[0363] JPEG2024544566000002.jpg243170JPEG2024544566000003.jpg239170JPEG2024544566000004.jpg245170JPEG2024544566000005.jpg245170

Claims

1. At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen, At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen, At least one nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen, and At least one nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen A lentiviral vector, particularly a non-integrating lentiviral vector, comprising at least four different nucleic acid sequences selected from the group consisting of:

2. 2. The lentiviral vector of claim 1, wherein the nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen encodes an amino acid sequence having at least 80% sequence identity with the amino acid sequence set forth as SEQ ID NO:7, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:

6.

3. 3. The lentiviral vector of claim 1 or 2, wherein the nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen encodes an amino acid sequence having at least 68% sequence identity with the amino acid sequence set forth as SEQ ID NO: 16, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO: 14 and SEQ ID NO:

15.

4. 4. The lentiviral vector according to any one of claims 1 to 3, wherein the nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen encodes an amino acid sequence having at least 60% sequence identity with the amino acid sequence set forth as SEQ ID NO:24, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:

23.

5. 5. The lentiviral vector according to any one of claims 1 to 4, wherein the nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen encodes an amino acid sequence having at least 83% sequence identity with the amino acid sequence set forth as SEQ ID NO: 33, wherein the nucleic acid sequence is in particular selected from the group consisting of SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO:

32.

6. The lentiviral vector of any one of claims 1 to 5, wherein the at least four different nucleic acid sequences encoding antigens are fused together to form a single antigen nucleic acid sequence encoding a single antigen fusion protein under the control of a single promoter sequence.

7. The at least four different nucleic acid sequences are in the following order from the 5' end to the 3' end: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E7 antigen - a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV16) protein E6 antigen - a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E7 antigen - a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV18) protein E6 antigen; (b) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E6 antigen—a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E6 antigen—a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E7 antigen—a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E7 antigen; (c) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E6 antigen; a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E6 antigen; a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E7 antigen; a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E7 antigen; and (d) a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E7 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV18) protein E6 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E7 antigen; a nucleic acid sequence encoding the non-oncogenic human papillomavirus (HPV16) protein E6 antigen. The lentiviral vector according to any one of claims 1 to 6, which is selected from the group consisting of:

8. The lentiviral vector according to any one of claims 1 to 7, wherein the order of the at least four different nucleic acid sequences from the 5' end to the 3' end is: (a) a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E7 antigen - a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 16) protein E6 antigen - a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E7 antigen - a nucleic acid sequence encoding a non-oncogenic human papillomavirus (HPV 18) protein E6 antigen.

9. 9. The lentiviral vector according to any one of claims 1 to 8, comprising a nucleic acid sequence encoding an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth as SEQ ID NO: 42, wherein said nucleic acid sequence is in particular nucleic acid sequence SEQ ID NO:

41.

10. 10. The lentiviral vector according to any one of claims 1 to 9, wherein the lentiviral vector is selected from the group consisting of the non-integrating lentiviral vectors deposited at the CNCM under the accession numbers I-5759, I-5760, I-5761 and I-5762, in particular the non-integrating lentiviral vector deposited at the CNCM under the accession number I-5759.

11. The lentiviral vector according to any one of claims 1 to 10, wherein the lentiviral vector comprises an MHC class I promoter, in particular a β2-microglobulin promoter.

12. A lentiviral vector according to any one of claims 1 to 11, wherein the lentiviral vector comprises a cPPT / CTS sequence, in particular the cPPT / CTS sequence set forth as nucleic acid sequence SEQ ID NO:

37.

13. The lentiviral vector of any one of claims 1 to 12, wherein the lentiviral vector comprises a 3' long terminal repeat (LTR) lacking a U3 promoter sequence.

14. The lentiviral vector according to any one of claims 1 to 13, wherein the lentiviral vector does not contain a constitutive enhancer sequence.

15. 15. The lentiviral vector of any one of claims 1 to 14, wherein the lentiviral vector comprises a mutated Woodchuck Hepatitis B Virus (WHV) post-transcriptional regulatory element (WPRE), in particular comprising said mutated form having the sequence set forth as nucleic acid sequence SEQ ID NO:

38.

16. A lentiviral vector particle, in particular a non-integrating lentiviral vector particle, comprising at least one lentiviral vector according to any one of claims 1 to 15.

17. The lentiviral vector particle of claim 16, wherein the lentiviral vector particle comprises a functional lentiviral integrase protein.

18. The lentiviral vector particle of claim 16 or 17, wherein the lentiviral vector particle comprises a vesicular stomatitis virus glycoprotein (VSVG), in particular a VSV-G Indiana serotype or a VSV-G New Jersey serotype.

19. The lentiviral vector particle of any one of claims 16 to 18, wherein the lentiviral vector particle comprises HIV-1 subtype D Gag and Pol proteins.

20. 20. An isolated cell comprising a lentiviral vector according to any one of claims 1 to 15 or a lentiviral vector particle according to any one of claims 16 to 19.

21. A vaccine composition comprising a lentiviral vector according to any one of claims 1 to 15, a lentiviral vector particle according to any one of claims 16 to 19, or a cell according to claim 20.

22. 22. A vaccine composition according to claim 21 for use in the treatment or prevention of HPV-induced cancers, in particular cancers selected from the group consisting of cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer, oropharyngeal cancer and metastases thereof, in particular lung metastases thereof.

23. A lentiviral vector according to any one of claims 1 to 15, a lentiviral vector particle according to any one of claims 16 to 19, or a cell according to claim 20 for use as a medicament or vaccine.

24. 24. The lentiviral vector, lentiviral vector particle or cell according to claim 23 for use in the treatment or prevention of HPV-induced cancer, in particular a cancer selected from the group consisting of cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer, oropharyngeal cancer and metastases thereof, in particular lung metastases thereof.

25. 25. The vaccine composition for use according to claim 22 or the lentiviral vector, lentiviral vector particle or cell for use according to claim 23 or 24, wherein the vaccine composition, lentiviral vector, lentiviral vector particle or cell is administered in combination with at least one immune checkpoint inhibitor, in particular in combination with at least one monoclonal antibody selected from the group consisting of anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-NKG2A, anti-TIM-3, anti-TIGIT and anti-LAG-3 monoclonal antibodies, more in particular in combination with at least one anti-PD-1 monoclonal antibody.

26. 26. The vaccine composition, lentiviral vector, lentiviral vector particle or cell for use according to claim 25, wherein the at least one immune checkpoint inhibitor is administered simultaneously or separately, in particular the at least one immune checkpoint inhibitor is administered at least 2 days, in particular at least 4 days, after administration of the vaccine composition, lentiviral vector, lentiviral vector particle or cell.

Citation Information

Cited By

  • Lentiviral vectors for the expression of human papillomavirus (HPV) antigens and their implementation in the treatment of HPV-induced cancers

    JP2025527186A